<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0"
    xmlns:content="http://purl.org/rss/1.0/modules/content/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>Cardiology — NAEOTOM Connect</title>
        <link>https://connect.siemens-healthineers.com/zh/</link>
        <pubDate>Sun, 25 Oct 2026 06:02:05 +0000</pubDate>
        <language>zh</language>
            <description>Cardiology — NAEOTOM Connect</description>
    <atom:link href="https://connect.siemens-healthineers.com/zh/discussions/tagged/cardiology/feed.rss" rel="self" type="application/rss+xml"/>
    <item>
        <title>(2026) Gkizas | PCCT-derived ECV quantifies myocardial fibrosis in HCM</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/602/2026-gkizas-pcct-derived-ecv-quantifies-myocardial-fibrosis-in-hcm</link>
        <pubDate>Sat, 24 Oct 2026 07:57:00 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">602@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 30 patients with genotype-confirmed hypertrophic cardiomyopathy, global PCCT-derived extracellular volume (ECV) closely matched cardiac MRI: 30.0 ± 4.8% vs 30.62 ± 4.2% (p = 0.59), with a small Bland–Altman bias of 0.6% and limits of agreement of −1.49% to 2.75%.</p><p></p><p>Agreement was also strong regionally, with segmental correlations of r = 0.89 at the base and r = 0.85 at both mid-ventricular and apical levels. Interobserver reproducibility was excellent for PCCT-derived ECV (ICC 0.982) and MRI-derived ECV (ICC 0.921).   </p><p></p><p>A global PCCT ECV threshold of 33.4% identified patients with LGE ≥15% with 80% sensitivity and 76% specificity (AUC 0.77). PCCT ECV also correlated with functional and biomarker severity, including peak VO₂ (r = −0.76) and NT-proBNP (r = 0.59), supporting its potential as a combined coronary and myocardial tissue-characterization biomarker. </p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS2211568425001640" rel="nofollow noopener ugc" role="button">Access publication</a></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/MX9WJ9HVMLKQ\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:591950,&quot;width&quot;:1000,&quot;height&quot;:575,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FMX9WJ9HVMLKQ%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1976,&quot;dateInserted&quot;:&quot;2026-10-24T07:56:12+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FMX9WJ9HVMLKQ%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/MX9WJ9HVMLKQ/image.png" alt="image.png" height="575" width="1000" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/MX9WJ9HVMLKQ/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/MX9WJ9HVMLKQ/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/MX9WJ9HVMLKQ/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/MX9WJ9HVMLKQ/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/MX9WJ9HVMLKQ/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/MX9WJ9HVMLKQ/image.png 2000w, https://us.v-cdn.net/6038601/uploads/MX9WJ9HVMLKQ/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Fig. 4. </strong>47-year-old man with hypertrophic cardiomyopathy due to MYBPC3 mutation (hematocrit level, 0.46 %).</p><p>(A) Short-axis view of late iodine enhancement (iodine map) with photon-counting CT.<br />
(B) Short-axis view of late gadolinium enhancement with cardiac MRI.<br />
(C-D) Extracellular volume polar maps (17-segment model of the American Heart Association) derived from C. Photon-counting CT and D. Cardiac MRI.    Eingefügter Text(20261024-07534…</p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Cardiac</p></td></tr><tr><td><p><strong>CCTA mode</strong></p></td><td><p>High-pitch or sequential, prospectively ECG-triggered depending on heart rate and rhythm</p></td></tr><tr><td><p><strong>tube voltage [kV]</strong></p></td><td><p>90</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>56</p></td></tr><tr><td><p><strong>reconstruction slice thickness [mm]</strong></p></td><td><p>0.4</p></td></tr><tr><td><p><strong> reconstruction increment [mm]</strong></p></td><td><p>0.4</p></td></tr><tr><td><p><strong>kernel</strong></p></td><td><p>Bv56</p></td></tr><tr><td><p><strong>iterative reconstruction</strong></p></td><td><p>QIR 4</p></td></tr><tr><td><p><strong>Late iodine enhancement mode</strong></p></td><td><p>High-pitch spectral acquisition</p></td></tr><tr><td><p><strong>Late iodine enhancement timing</strong></p></td><td><p>5 min after reinjection</p></td></tr><tr><td><p><strong>Late iodine enhancement tube voltage [kV]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>Late iodine enhancement IQ level</strong></p></td><td><p>100</p></td></tr><tr><td><p><strong>ECG gating / phase</strong></p></td><td><p>ECG-triggered, fixed absolute RR interval 280 ms</p></td></tr><tr><td><p><strong>VMI</strong></p></td><td><p>40 keV</p></td></tr><tr><td><p><strong>LIE reconstruction slice thickness [mm]</strong></p></td><td><p>2</p></td></tr><tr><td><p><strong>LIE reconstruction increment [mm]</strong></p></td><td><p>1</p></td></tr><tr><td><p><strong>LIE kernel</strong></p></td><td><p>Qr44</p></td></tr><tr><td><p><strong>LIE iterative reconstruction</strong></p></td><td><p>QIR 4</p></td></tr><tr><td><p><strong>Spectral reconstruction</strong></p></td><td><p>Iodine maps</p></td></tr><tr><td><p><strong>Contrast</strong></p></td><td><p>Iobitridol 350 mg I/mL</p></td></tr><tr><td><p><strong>CCTA contrast volume</strong></p></td><td><p>50 mL</p></td></tr><tr><td><p><strong>LIE contrast volume</strong></p></td><td><p>Additional 50 mL</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>4–5 mL/s</p></td></tr><tr><td><p><strong>Saline flush</strong></p></td><td><p>20 mL</p></td></tr><tr><td><p><strong>Post-processing</strong></p></td><td><p>syngo.via VB40A; prototype Frontier Cardiac Functional Analyses for ECV</p></td></tr><tr><td><p><strong>Late-scan DLP [mGy·cm]</strong></p></td><td><p>106 ± 52</p></td></tr><tr><td><p><strong>Late-scan effective dose [mSv]</strong></p></td><td><p>1.47 ± 0.6</p></td></tr></table></div><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p><strong>30 patients</strong>, 22 men; mean age ~59 years</p></td></tr><tr><td><p><strong>Global ECV</strong></p></td><td><p>PCCT <strong>30.0 ± 4.8%</strong> vs MRI <strong>30.62 ± 4.2%</strong>, <em>p</em> = 0.59</p></td></tr><tr><td><p><strong>PCCT–MRI agreement</strong></p></td><td><p>Bias <strong>0.6%</strong>, limits of agreement <strong>−1.49% to 2.75%</strong></p></td></tr><tr><td><p><strong>Segmental correlation</strong></p></td><td><p>Basal <strong>r = 0.89</strong>; mid-ventricular <strong>r = 0.85</strong>; apical <strong>r = 0.85</strong></p></td></tr><tr><td><p><strong>ECV threshold for LGE ≥15%</strong></p></td><td><p><strong>33.4%</strong>; sensitivity <strong>80%</strong>, specificity <strong>76%</strong>, AUC <strong>0.77</strong></p></td></tr><tr><td><p><strong>Clinical correlations</strong></p></td><td><p>Peak VO₂ <strong>r = −0.76</strong>; NT-proBNP <strong>r = 0.59</strong></p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
Gkizas C, Longere B, Bechrouri S, Ridon H, Rodriguez Musso A, Haidar M, Croisille C, Montaigne D, De Groote P, Pontana F. <em>Photon-counting CT myocardial extracellular volume: A non-invasive biomarker for fibrosis in patients with hypertrophic cardiomyopathy.</em> <strong>Diagnostic and Interventional Imaging.</strong> 2026;107(1):17–24. doi:10.1016/j.diii.2025.09.001. </p>]]>
        </description>
    </item>
    <item>
        <title>(2026) Hellms | Non-gated pediatric cardiac PCCT cuts dose while preserving image quality</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/562/2026-hellms-non-gated-pediatric-cardiac-pcct-cuts-dose-while-preserving-image-quality</link>
        <pubDate>Mon, 19 Oct 2026 04:00:53 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">562@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 37 children with congenital heart disease matched to 37 EID-CT controls by water-equivalent diameter, <strong>non-ECG-gated high-pitch PCCT substantially reduced radiation exposure</strong>: CTDIvol 0.20 ± 0.12 vs 0.37 ± 0.17 mGy and DLP 4.06 ± 3.22 vs 7.21 ± 4.67 mGy·cm (p &lt; 0.001 for both), corresponding to roughly 46% and 44% reductions, respectively.</p><p></p><p>Despite the lower dose, SNR, CNR, beam-hardening artifacts, overall subjective image quality, and proximal coronary-artery visualization were not significantly different between PCCT and EID-CT.<strong> This was achieved with an extremely fast 70-kV, pitch-3.2, non-ECG-gated PCCT acquisition</strong>. </p><p></p><p>The practical implication is particularly relevant for infants and young children requiring repeated cardiovascular imaging: sub-second, free-breathing cardiac PCCT can <strong>preserve diagnostic anatomy without ECG gating at very low radiation dose</strong>. However, patients with visible metallic devices were excluded, and the retrospective cohort was relatively small.  </p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00330-025-11719-6" rel="nofollow noopener ugc" role="button">Access publication</a></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/LWX6KP8C9WWQ\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:929412,&quot;width&quot;:2000,&quot;height&quot;:1150,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FLWX6KP8C9WWQ%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1868,&quot;dateInserted&quot;:&quot;2026-10-15T16:18:27+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FLWX6KP8C9WWQ%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/LWX6KP8C9WWQ/image.png" alt="image.png" height="1150" width="2000" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/LWX6KP8C9WWQ/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/LWX6KP8C9WWQ/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/LWX6KP8C9WWQ/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/LWX6KP8C9WWQ/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/LWX6KP8C9WWQ/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/LWX6KP8C9WWQ/image.png 2000w, https://us.v-cdn.net/6038601/uploads/LWX6KP8C9WWQ/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 4. </strong>A, B Cardiac examination on photon-counting detector CT of a 7-month-old female patient, born with tetralogy of Fallot. Volume CT dose index (CTDIvol) of this examination was 0.11 mGy, dose length product (DLP) was 1.9 mGy<em>cm, water-equivalent diameter was 118 mm. C, D Cardiac examination on energy-integrating detector CT of a 5-month-old female patient, born with atrioventricular septal defect. CTDIvol of this examination was 0.35 mGy, DLP was 5.8 mGy</em>cm, water-equivalent diameter was 118 mm. The cardiac anatomy can be very well depicted in both studies, including the coronary arteries (arrows in the axial orientations A and C). B and D show the aortic arch in parasagittal orientation.</p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>PCCT</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Whole thorax and heart</p></td></tr><tr><td><p><strong>Patient position</strong></p></td><td><p>Supine, arms elevated</p></td></tr><tr><td><p><strong>Scan direction</strong></p></td><td><p>Craniocaudal</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>Quantum Fast high-pitch helical</p></td></tr><tr><td><p><strong>ECG gating</strong></p></td><td><p>None</p></td></tr><tr><td><p><strong>Breathing</strong></p></td><td><p>Free-breathing</p></td></tr><tr><td><p><strong>Tube voltage [kV]</strong></p></td><td><p><strong>70</strong></p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p><strong>45</strong></p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>Automated exposure control</p></td></tr><tr><td><p><strong>CTDIvol [mGy]</strong></p></td><td><p><strong>0.20 ± 0.12</strong></p></td></tr><tr><td><p><strong>DLP [mGy·cm]</strong></p></td><td><p><strong>4.06 ± 3.22</strong></p></td></tr><tr><td><p><strong>Rotation time [s]</strong></p></td><td><p><strong>0.25</strong></p></td></tr><tr><td><p><strong>Pitch</strong></p></td><td><p><strong>3.2</strong></p></td></tr><tr><td><p><strong>Detector slice collimation [mm]</strong></p></td><td><p><strong>144 × 0.4</strong></p></td></tr><tr><td><p><strong>Matrix</strong></p></td><td><p><strong>768 × 768</strong></p></td></tr><tr><td><p><strong>Reconstruction slice thickness [mm]</strong></p></td><td><p><strong>1.0</strong></p></td></tr><tr><td><p><strong>Reconstruction increment [mm]</strong></p></td><td><p><strong>0.7</strong></p></td></tr><tr><td><p><strong>Kernel</strong></p></td><td><p><strong>Br40</strong></p></td></tr><tr><td><p><strong>Iterative reconstruction</strong></p></td><td><p><strong>QIR 2</strong></p></td></tr><tr><td><p><strong>Contrast</strong></p></td><td><p>Iomeprol 400</p></td></tr><tr><td><p><strong>Contrast volume</strong></p></td><td><p><strong>7 mL</strong> at 3–6 kg; <strong>1 mL/kg</strong> at ≥7 kg</p></td></tr><tr><td><p><strong>Saline</strong></p></td><td><p>Saline flush</p></td></tr><tr><td><p><strong>Bolus triggering</strong></p></td><td><p>Bolus tracking; scan initiated when all four cardiac chambers were optimally opacified</p></td></tr><tr><td><p><strong>Acquisition time</strong></p></td><td><p>&lt;1 s on average</p></td></tr></table></div><p>The study used a CARE keV <strong>Image Quality level of 45</strong> as the PCCT reference-mAs control parameter. Acquisition was performed without ECG triggering, using free-breathing high-pitch scanning. </p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>PCCT vs EID-CT</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p><strong>37 vs 37</strong> size-matched children</p></td></tr><tr><td><p><strong>CTDIvol</strong></p></td><td><p><strong>0.20 ± 0.12 vs 0.37 ± 0.17 mGy</strong>, <em>p</em> &lt; 0.001</p></td></tr><tr><td><p><strong>DLP</strong></p></td><td><p><strong>4.06 ± 3.22 vs 7.21 ± 4.67 mGy·cm</strong>, <em>p</em> &lt; 0.001</p></td></tr><tr><td><p><strong>Dose reduction</strong></p></td><td><p>Approximately <strong>46% lower CTDIvol</strong> and <strong>44% lower DLP</strong></p></td></tr><tr><td><p><strong>Quantitative image quality</strong></p></td><td><p>No significant difference in <strong>SNR, CNR, or beam-hardening artifacts</strong></p></td></tr><tr><td><p><strong>Qualitative image quality</strong></p></td><td><p>No significant difference in overall image quality or proximal coronary visualization</p></td></tr></table></div><p><strong>Source:</strong><br />
Hellms S, Werncke T, Böttcher J, Happel CM, Eckstein J, Krueger MB, Panknin C, Pfeil A, Kaireit TF, Beerbaum P, Vogel-Claussen J, Wacker F, Renz DM. <em>Reduction of radiation exposure and preserved image quality using photon-counting detector cardiac computed tomography without electrocardiographic gating in children with congenital heart disease.</em> <strong>European Radiology.</strong> 2026;36:324–333. doi:10.1007/s00330-025-11719-6.</p>]]>
        </description>
    </item>
    <item>
        <title>PCCT for coronary assessment and functional imaging in Takotsubo cardiomyopathy</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/511/pcct-for-coronary-assessment-and-functional-imaging-in-takotsubo-cardiomyopathy</link>
        <pubDate>Thu, 01 Oct 2026 10:02:30 +0000</pubDate>
        <category>Case reports</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">511@/zh/discussions</guid>
        <description><![CDATA[<h3 data-id="balint-szilveszter-borbala-vattay-peter-csongor-milan-vecsey-nagy"><a data-username="Bálint Szilveszter" data-userid="159" rel="nofollow" href="https://connect.siemens-healthineers.com/zh/profile/159/B%C3%A1lint%20Szilveszter">@Bálint Szilveszter</a>, Borbála Vattay, Péter Csongor,  <a data-username="Milan Vecsey-Nagy" data-userid="755" rel="nofollow" href="https://connect.siemens-healthineers.com/zh/profile/755/Milan%20Vecsey-Nagy">@Milan Vecsey-Nagy</a><br /></h3><h4 data-id="varosmajor-heart-and-vascular-centre-cardiac-ct-working-group-budapest-hungary">Városmajor Heart and Vascular Centre, Cardiac CT Working Group, Budapest, Hungary</h4><h4 data-id="september-29-2026">September 29, 2026</h4><p></p><div data-embedjson="{&quot;height&quot;:&quot;360&quot;,&quot;width&quot;:&quot;640&quot;,&quot;isKnowledge&quot;:false,&quot;url&quot;:&quot;https:\/\/siemens-healthineers.bynder.com\/asset\/a85e1bdc-bf2b-4a4d-94a0-dc890f0a7651\/CT-NAEOTOM-CONNECT-CaseReport-Takutsobu-2-VIDEO-2026.mp4&quot;,&quot;embedType&quot;:&quot;iframe&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fsiemens-healthineers.bynder.com%2Fasset%2Fa85e1bdc-bf2b-4a4d-94a0-dc890f0a7651%2FCT-NAEOTOM-CONNECT-CaseReport-Takutsobu-2-VIDEO-2026.mp4" rel="nofollow noopener ugc">
        https://siemens-healthineers.bynder.com/asset/a85e1bdc-bf2b-4a4d-94a0-dc890f0a7651/CT-NAEOTOM-CONNECT-CaseReport-Takutsobu-2-VIDEO-2026.mp4
    </a>
</div><div data-embedjson="{&quot;height&quot;:&quot;360&quot;,&quot;width&quot;:&quot;640&quot;,&quot;isKnowledge&quot;:false,&quot;url&quot;:&quot;https:\/\/siemens-healthineers.bynder.com\/asset\/377c2032-a4c9-4561-9e4f-d6479c6dbd1d\/CT-NAEOTOM-CONNECT-CaseReport-Takutsobu-1-VIDEO-2026.mp4&quot;,&quot;embedType&quot;:&quot;iframe&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fsiemens-healthineers.bynder.com%2Fasset%2F377c2032-a4c9-4561-9e4f-d6479c6dbd1d%2FCT-NAEOTOM-CONNECT-CaseReport-Takutsobu-1-VIDEO-2026.mp4" rel="nofollow noopener ugc">
        https://siemens-healthineers.bynder.com/asset/377c2032-a4c9-4561-9e4f-d6479c6dbd1d/CT-NAEOTOM-CONNECT-CaseReport-Takutsobu-1-VIDEO-2026.mp4
    </a>
</div><p></p><h2 data-id="history">History</h2><h4 data-id="why-did-the-patient-come-for-a-ct-exam">Why did the patient come for a CT exam?</h4><p>A 63-year-old female patient, presenting with typical chest pain, was referred for coronary imaging to clarify her coronary status and exclude acute coronary syndrome.</p><p>Laboratory tests showed marked myocardial injury and neurohormonal activation, with highly elevated high-sensitivity troponin I of 2032 ng/L, CK of 565 U/L, CK-MB of 43 U/L, and NT-proBNP of 1589.7 pg/mL.</p><p>Mild inflammatory activity was also present, with leukocytosis of 12.86 G/L, neutrophilia, and mildly elevated CRP of 6.2 mg/L. Renal function was preserved, with an eGFR of 107 mL/min.</p><p>An initial transthoracic echocardiography showed mildly to moderately reduced global left ventricular systolic function, with a left ventricular ejection fraction of 42% by Simpson’s method. Regional wall motion abnormalities were present, with hypokinesis of the midventricular segments and near akinesia of the apical third of the left ventricle. Mild mitral regurgitation and moderate tricuspid regurgitation were present.</p><p>Right ventricular size was normal, and right ventricular longitudinal systolic function was preserved. The estimated pulmonary artery systolic pressure was mildly elevated.</p><p>Coronary CT angiography (CCTA) was recommended to exclude obstructive coronary artery disease.</p><p></p><h2 data-id="diagnosis">Diagnosis</h2><h4 data-id="what-were-the-ct-findings-and-what-happened-to-the-patient-after-ct">What were the CT findings, and what happened to the patient after CT?</h4><p>Coronary CT angiography was performed using a dual-source photoncounting detector CT scanner (Siemens NAEOTOM Alpha Peak).</p><p>The estimated CCTA radiation dose was 397 mGy·cm. Iomeron 400 was administered with a contrast volume of 90 mL and a flow of 5.5 ml/s. The patient received 0.8 mg sublingual nitroglycerin prior to the examination. Heart rate during the scan was 93–97/min with sinus rhythm.</p><p>The coronary calcium score was 4.</p><p>The patient had a left-dominant coronary artery system and normal origin and course of the coronary arteries. No relevant coronary atherosclerosis or luminal stenosis were detected. Only minimal vessel wall irregularities were observed, with small specks of calcified plaque in the distal left anterior descending (LAD) artery (Figure 1. and 2.)</p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/F7ZVE7HEDSFS\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:1518105,&quot;width&quot;:2000,&quot;height&quot;:1150,&quot;displaySize&quot;:&quot;medium&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FF7ZVE7HEDSFS%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1716,&quot;dateInserted&quot;:&quot;2026-09-03T08:50:20+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FF7ZVE7HEDSFS%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/F7ZVE7HEDSFS/image.png" alt="image.png" height="1150" width="2000" data-display-size="medium" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/F7ZVE7HEDSFS/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/F7ZVE7HEDSFS/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/F7ZVE7HEDSFS/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/F7ZVE7HEDSFS/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/F7ZVE7HEDSFS/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/F7ZVE7HEDSFS/image.png 2000w, https://us.v-cdn.net/6038601/uploads/F7ZVE7HEDSFS/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 1.</strong> CT coronary angiography demonstrating<br />&#13; normal coronary artery anatomy with no<br />&#13; evidence of a significant stenosis.</p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/20KUJCL6DHDD\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:40075,&quot;width&quot;:526,&quot;height&quot;:219,&quot;displaySize&quot;:&quot;medium&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F20KUJCL6DHDD%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1714,&quot;dateInserted&quot;:&quot;2026-09-03T08:34:15+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F20KUJCL6DHDD%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/20KUJCL6DHDD/image.png" alt="image.png" height="219" width="526" data-display-size="medium" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/20KUJCL6DHDD/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/20KUJCL6DHDD/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/20KUJCL6DHDD/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/20KUJCL6DHDD/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/20KUJCL6DHDD/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/20KUJCL6DHDD/image.png 2000w, https://us.v-cdn.net/6038601/uploads/20KUJCL6DHDD/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 2.</strong> Electrocardiogram (ECG) during Prospective<br />&#13; Sequential Cardiac CT Acquisition.</p><p></p><p>Coronary CT angiography was performed using a prospectively ECG-triggered sequential axial acquisition. Given the patient’s heart rate, exceeding 90 beats/min, multiphase image reconstruction was performed to ensure optimal image quality and to allow simultaneous assessment of coronary anatomy and left ventricular function.</p><p>In addition to coronary artery evaluation, the multiphase datasets were analyzed for regional wall-motion abnormalities and cardiac chamber volumetry.</p><p>Coronary analysis demonstrated non-obstructive coronary artery disease, with only minimal calcified plaque in the distal left anterior descending artery. Functional assessment revealed severe apical hypokinesis/akinesis with associated midventricular dyskinesis and preserved basal contractility, resulting in the characteristic apical ballooning pattern of a classical Takotsubo syndrome (Figure 3).</p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/BZXXKYQSKXYQ\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:169153,&quot;width&quot;:964,&quot;height&quot;:360,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FBZXXKYQSKXYQ%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1715,&quot;dateInserted&quot;:&quot;2026-09-03T08:34:58+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FBZXXKYQSKXYQ%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/BZXXKYQSKXYQ/image.png" alt="image.png" height="360" width="964" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/BZXXKYQSKXYQ/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/BZXXKYQSKXYQ/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/BZXXKYQSKXYQ/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/BZXXKYQSKXYQ/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/BZXXKYQSKXYQ/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/BZXXKYQSKXYQ/image.png 2000w, https://us.v-cdn.net/6038601/uploads/BZXXKYQSKXYQ/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 3. </strong>Left Ventricular Apical Dysfunction Consistent with Takotsubo Pattern on Multiphase Cardiac CT Functional<br />&#13; Analysis. Multiphase cardiac CT-derived left ventricular wall-motion bull’s-eye map demonstrating a regional<br />&#13; gradient of myocardial contractility with preserved basal function (red–yellow), reduced mid-ventricular motion,<br />&#13; and markedly impaired apical wall motion (blue–purple). The pattern shows an apical-dominant distribution of<br />&#13; dysfunction, consistent with a classical Takotsubo-type contraction abnormality in the appropriate clinical context<br />&#13; (left). Mildly increased left ventricular end-diastolic and end-systolic volume indices (indexed to body surface area)<br />&#13; were detected, with mildly reduced systolic function (LVEF 45%) based on the available cardiac phases.</p><p>Mildly increased left ventricular end-diastolic and end-systolic volume indices were detected, with mildly reduced systolic function (LVEF 45%).</p><p>As an incidental extracardiac finding, scattered bilateral ground-glass opacities with patchy consolidations were detected, most consistent with bronchopneumonia given the elevated inflammatory laboratory markers.</p><p></p><h2 data-id="comments">Comments</h2><h4 data-id="is-there-any-clinically-interesting-aspect-of-the-case-to-discuss-what-difference-did-photon-counting-ct-make-for-the-patient">Is there any clinically interesting aspect of the case to discuss? <br />
What difference did photon-counting CT make for the patient?</h4><p>This case highlights the clinical value of the photon-counting coronary CT angiography in the diagnostic work-up of patients presenting with acute chest pain, elevated cardiac biomarkers, and electrocardiographic changes suggestive of acute coronary syndrome.</p><p>Beyond excluding obstructive coronary artery disease, CT angiography enables comprehensive myocardial functional assessment, allowing identification of the characteristic apical ballooning pattern consistent with Takotsubo syndrome, thereby supporting a working diagnosis of MINOCA – now defined as myocardial injury with non-obstructive coronary arteries (Fifth Universal Definition of Myocardial Infarction, 2026) – with Takotsubo syndrome as the most likely final diagnosis.</p><p>The ability of photon-counting CT to simultaneously evaluate coronary anatomy, plaque burden, and left ventricular function in a single examination may facilitate rapid differentiation between obstructive coronary disease and alternative causes of acute myocardial injury, potentially reducing the need for additional imaging or invasive angiography in selected patients.</p><p>This case also demonstrates the technical advantages of photoncounting coronary CT angiography for combined coronary and functional cardiac assessment in an acute setting.</p><p>The system provides excellent spatial and temporal resolution, enabling high-quality coronary plaque evaluation, even at elevated heart rates (&gt;90 beats/min), with minimal motion artefact. This allows for a reliable assessment of the coronary lumen and detection of only minimal calcified plaque in the distal LAD.</p><p>In addition, multiphase ECG-gated reconstructions offer excellent temporal resolution for detailed motion analysis of all cardiac chambers, permitting accurate depiction of regional wall-motion abnormalities.</p><p>Overall, the combination of high spatial fidelity for plaque characterization and high temporal resolution for functional assessment underscores the robustness of photon-counting CT for integrated “one-stop” coronary and myocardial evaluation, even under challenging heart rate conditions.</p><p>Note that the role of CT in this case should be interpreted within its limits. CCTA was requested to rule out obstructive coronary artery disease in a haemodynamically stable patient; because of the elevated heart rate, a multiphase acquisition was used, which additionally depicted the wall-motion pattern. CCTA can therefore exclude obstructive coronary artery disease and further reinforce echocardiographic findings suggestive of Takotsubo syndrome, but it does not establish the diagnosis on its own. Current recommendations advise cardiac magnetic resonance imaging when the final diagnosis remains uncertain—particularly in the presence of inflammatory red flags—and follow-up echocardiography to document recovery of left ventricular function. In our patient, who was referred to our centre for CT only, further diagnostic work-up and follow-up were performed at the referring institution.</p><p></p><h2 data-id="examination-protocol">Examination Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><td><p><strong>Scanner</strong></p></td><td><p><strong>NAEOTOM Alpha.Peak</strong></p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Heart</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>QuantumPlus</p></td></tr><tr><td><p><strong>Scan length</strong></p></td><td><p>126 mm</p></td></tr><tr><td><p><strong>Scan direction</strong></p></td><td><p>Cranio-caudal</p></td></tr><tr><td><p><strong>Scan time</strong></p></td><td><p>2,38 s</p></td></tr><tr><td><p><strong>Tube voltage</strong></p></td><td><p>140 kV</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>65</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>CARE Dose4D</p></td></tr><tr><td><p><strong>CTDIvol</strong></p></td><td><p>31.5 mGy</p></td></tr><tr><td><p><strong>DLP</strong></p></td><td><p>397 mGy*cm</p></td></tr><tr><td><p><strong>Rotation time</strong></p></td><td><p>0.25 s</p></td></tr><tr><td><p><strong>Pitch</strong></p></td><td><p>not applicable</p></td></tr><tr><td><p><strong>Slice collimation</strong></p></td><td><p>0.4 mm</p></td></tr><tr><td><p><strong>Slice width</strong></p></td><td><p>0.4 mm</p></td></tr><tr><td><p><strong>Reconstruction increment</strong></p></td><td><p>0.4 mm</p></td></tr><tr><td><p><strong>Reconstruction kernel</strong></p></td><td><p>Bv56 Q4</p></td></tr><tr><td><p><strong>keV level</strong></p></td><td><p>55</p></td></tr><tr><td><p><strong>Spectral reconstruction</strong></p></td><td><p>Monoenergetic Plus</p></td></tr><tr><td><p><strong>Heart rate</strong></p></td><td><p>95/min</p></td></tr><tr><td><p><strong>Contrast</strong></p></td><td><p>Iomeron 400, 400 mg/mL</p></td></tr><tr><td><p><strong>Volume</strong></p></td><td><p>95 mL + 10mL saline pacer + 30mL saline chaser</p></td></tr><tr><td><p><strong>Flow rate</strong></p></td><td><p>5.5 mL/s</p></td></tr><tr><td><p><strong>Start delay</strong></p></td><td><p>Bolus tracking triggered at 140 HU (CCTA)</p></td></tr></table></div><p></p><h2 data-id="disclaimer">DISCLAIMER</h2><p>The statements by customers of Siemens Healthineers described herein are based on results that were achieved in the customer’s unique setting. Because there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results.</p><p>The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.</p>]]>
        </description>
    </item>
    <item>
        <title>PCCT for myocardial tissue characterization in acute myocarditis: comparison with CMR</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/512/pcct-for-myocardial-tissue-characterization-in-acute-myocarditis-comparison-with-cmr</link>
        <pubDate>Mon, 28 Sep 2026 20:07:05 +0000</pubDate>
        <category>Case reports</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">512@/zh/discussions</guid>
        <description><![CDATA[<p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/0NA911YUF6CE\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:285496,&quot;width&quot;:581,&quot;height&quot;:339,&quot;displaySize&quot;:&quot;inline&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F0NA911YUF6CE%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1720,&quot;dateInserted&quot;:&quot;2026-09-03T08:59:40+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_inline&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F0NA911YUF6CE%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/0NA911YUF6CE/image.png" alt="image.png" height="339" width="581" data-display-size="inline" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/0NA911YUF6CE/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/0NA911YUF6CE/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/0NA911YUF6CE/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/0NA911YUF6CE/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/0NA911YUF6CE/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/0NA911YUF6CE/image.png 2000w, https://us.v-cdn.net/6038601/uploads/0NA911YUF6CE/image.png" sizes="100vw" /></a>
    </span>
</span>
 </p><h3 data-id="ferenc-imre-suhai-barbara-sipos-milan-vecsey-nagy-balint-szilveszter">Ferenc Imre Suhai, Barbara Sipos, Milán Vecsey-Nagy, Bálint Szilveszter<br /></h3><h4 data-id="varosmajor-heart-and-vascular-centre-cardiac-ct-working-group-budapest-hungary">Városmajor Heart and Vascular Centre, Cardiac CT Working Group, Budapest, Hungary</h4><h4 data-id="september-29-2026">September 29, 2026</h4><p></p><div data-embedjson="{&quot;height&quot;:&quot;360&quot;,&quot;width&quot;:&quot;640&quot;,&quot;isKnowledge&quot;:false,&quot;url&quot;:&quot;https:\/\/siemens-healthineers.bynder.com\/asset\/2a67d11b-415e-4e25-a74a-42d82ff7a4d5\/CT-NAEOTOM-CONNECT-CaseReport-BalintMyocard-1-VIDEO-2026.mp4&quot;,&quot;embedType&quot;:&quot;iframe&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fsiemens-healthineers.bynder.com%2Fasset%2F2a67d11b-415e-4e25-a74a-42d82ff7a4d5%2FCT-NAEOTOM-CONNECT-CaseReport-BalintMyocard-1-VIDEO-2026.mp4" rel="nofollow noopener ugc">
        https://siemens-healthineers.bynder.com/asset/2a67d11b-415e-4e25-a74a-42d82ff7a4d5/CT-NAEOTOM-CONNECT-CaseReport-BalintMyocard-1-VIDEO-2026.mp4
    </a>
</div><div data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/3BV4MQZ2KVN7\/26-358-cr-photoncountingct-myocardial-tissue.pdf&quot;,&quot;name&quot;:&quot;26-358_CR_PhotonCountingCT_Myocardial_Tissue.pdf&quot;,&quot;type&quot;:&quot;application\/pdf&quot;,&quot;size&quot;:619666,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F3BV4MQZ2KVN7%2F26-358-cr-photoncountingct-myocardial-tissue.pdf&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1723,&quot;dateInserted&quot;:&quot;2026-09-03T09:10:09+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;file&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <a rel="nofollow" href="https://connect.siemens-healthineers.com/api/v2/media/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F3BV4MQZ2KVN7%2F26-358-cr-photoncountingct-myocardial-tissue.pdf" download="" aria-label="26-358_CR_PhotonCountingCT_Myocardial_Tissue.pdf">
        26-358_CR_PhotonCountingCT_Myocardial_Tissue.pdf
    </a>
</div>
<h2 data-id="history">History</h2><h4 data-id="why-did-the-patient-come-for-a-ct-exam">Why did the patient come for a CT exam?</h4><p>A 29-year-old male patient, with a history of hypertension and bronchial asthma, was referred to the Városmajor Heart and Vascular Centre from the emergency department due to acute retrosternal chest pain and markedly elevated cardiac biomarkers.</p><p>His symptoms occurred in the setting of a recent upper respiratory tract infection with fever and follicular tonsillitis. He had been treated with azithromycin before admission.</p><p>At the emergency department, laboratory tests showed significant inflammatory activity and myocardial injury, with elevated C-reactive protein, leukocytosis with neutrophilia, and markedly elevated high-sensitivity troponin T, which increased from 1302 ng/L to 1689 ng/L. CK-MB was also elevated.</p><p>Electrocardiography showed ST-segment elevation in the inferior leads with reciprocal ST depression in aVL.</p><p>Transthoracic echocardiography revealed preserved left ventricular systolic function without regional wall motion abnormalities. Given the combination of acute chest pain, elevated troponin, inflammatory syndrome, and ECG changes, acute myocarditis was suspected; however, acute coronary syndrome had to be excluded.</p><p>Therefore, a coronary CT angiography was performed as the initial imaging modality to assess the coronary status. Cardiac magnetic resonance imaging was subsequently performed for detailed myocardial tissue characterization and confirmation of the diagnosis.</p><p></p><h2 data-id="diagnosis">Diagnosis</h2><h4 data-id="what-were-the-ct-findings-and-what-happened-to-the-patient-after-ct">What were the CT findings, and what happened to the patient after CT?</h4><p>Coronary CT angiography was performed using a photon-counting detector CT on a Siemens NAEOTOM Alpha Peak scanner. Native calcium scoring, contrast-enhanced ECG-gated coronary CTA, and a 6-minute delayed-phase acquisition for myocardial tissue characterization and visual assessment of late iodine enhancement were performed.</p><p>The estimated radiation dose was 350 mGy·cm for the CCTA and 245 mGy·cm for the delayed scan.</p><p>Iomeron 400 was administered with a contrast volume of 80 mL. The patient received 75 mg oral metoprolol and 0.8 mg sublingual nitroglycerin prior to the examination. Heart rate during the scan was 85/min with sinus rhythm.</p><p>The coronary calcium score was 0.</p><p>The patient had a left-dominant coronary artery system and normal origin and course of the coronary arteries. No relevant coronary atherosclerosis or luminal stenosis were detected (Figure 1).</p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/EXORB42PL2G3\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:519928,&quot;width&quot;:1091,&quot;height&quot;:641,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FEXORB42PL2G3%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1717,&quot;dateInserted&quot;:&quot;2026-09-03T08:57:07+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FEXORB42PL2G3%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/EXORB42PL2G3/image.png" alt="image.png" height="641" width="1091" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/EXORB42PL2G3/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/EXORB42PL2G3/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/EXORB42PL2G3/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/EXORB42PL2G3/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/EXORB42PL2G3/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/EXORB42PL2G3/image.png 2000w, https://us.v-cdn.net/6038601/uploads/EXORB42PL2G3/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 1. </strong>CT coronary angiography demonstrating normal coronary artery anatomy with no evidence of significant stenosis.</p><p></p><p>Cardiac magnetic resonance imaging was performed on a 1.5-T Siemens Aera scanner. Short-axis images demonstrate myocardial edema on T2-weighted fat-suppressed imaging and corresponding non-ischemic late gadolinium enhancement on LGE imaging in the mid-ventricular anterior-anterolateral and inferior-inferolateral left ventricular segments, predominantly in a subepicardial to midmyocardial distribution.</p><p>The concordant presence of edema and LGE supports acute myocarditis rather than ischemic infarction.</p><p>On the 6-minute delayed-phase PCCT images, visually detectable late iodine enhancement was observed, in a non-ischemic distribution. The enhancement involved the basal and midventricular anterolateral and inferolateral regions, the inferior segment in a subepicardial to midmyocardial pattern, and the apical inferior and lateral segments (Figure 2).</p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/AMJGJSANT6IR\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:285496,&quot;width&quot;:581,&quot;height&quot;:339,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FAMJGJSANT6IR%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1718,&quot;dateInserted&quot;:&quot;2026-09-03T08:57:48+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FAMJGJSANT6IR%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/AMJGJSANT6IR/image.png" alt="image.png" height="339" width="581" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/AMJGJSANT6IR/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/AMJGJSANT6IR/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/AMJGJSANT6IR/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/AMJGJSANT6IR/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/AMJGJSANT6IR/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/AMJGJSANT6IR/image.png 2000w, https://us.v-cdn.net/6038601/uploads/AMJGJSANT6IR/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 2. </strong>Electrocardiogram (ECG) During Prospective Sequential Cardiac CT Acquisition. Multimodality comparison of an acute myocardial injury from basal to apical short-axis images. The first column shows 6-minute delayed-phase PCCT images, the second column shows corresponding color-coded LUT maps, the third column shows iodine maps, and the fourth column shows matched cardiac MRI late gadolinium enhancement images. Blue arrows indicate areas of abnormal myocardial iodine enhancement on PCCT and corresponding non-ischemic myocardial injury on CMR. The abnormalities are predominantly located in the anterolateral, inferolateral, and inferior left ventricular segments, with a subepicardial to midmyocardial distribution, consistent with acute myocarditis.</p><p></p><p>The visual delayed iodine enhancement pattern indicated abnormal myocardial tissue characteristics and supported the diagnosis of an acute myocarditis.</p><p>Cardiac magnetic resonance (CMR) imaging was performed on a 1.5-T Siemens Aera scanner using Gadovist contrast agent. The CMR protocol included cine b-SSFP imaging, T2-weighted imaging, native T1 and T2 mapping, first-pass perfusion, late gadolinium enhancement imaging, and post-contrast T1 mapping for extracellular volume assessment.</p><p>CMR demonstrated mildly reduced left ventricular systolic function, with an LVEF of 45.4%. Left ventricular volumes were within the normal range, stroke volume was preserved, and left ventricular myocardial mass was normal. Right ventricular size and systolic function were preserved, with an RVEF of 52.2%.</p><p>T2-weighted images demonstrated myocardial edema in the basal and midventricular anterolateral and inferolateral segments, the midventricular inferior and partly anterior segments, and the apical inferior segment, predominantly in a subepicardial to midmyocardial distribution (Figure 3).</p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/X3RIEB831IY0\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:146490,&quot;width&quot;:898,&quot;height&quot;:383,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FX3RIEB831IY0%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1719,&quot;dateInserted&quot;:&quot;2026-09-03T08:59:00+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FX3RIEB831IY0%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/X3RIEB831IY0/image.png" alt="image.png" height="383" width="898" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/X3RIEB831IY0/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/X3RIEB831IY0/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/X3RIEB831IY0/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/X3RIEB831IY0/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/X3RIEB831IY0/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/X3RIEB831IY0/image.png 2000w, https://us.v-cdn.net/6038601/uploads/X3RIEB831IY0/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 3. </strong>Cardiac MRI confirmation of acute myocarditis: myocardial edema and non-ischemic injury</p><p></p><p>After gadolinium administration, pathological late gadolinium enhancement was observed in the same edematous myocardial segments.</p><p>Parametric mapping further supported the diagnosis. Native T1, T2, and ECV values were elevated in the affected lateral myocardial regions. ECV was increased in the basal lateral wall and midventricular lateral wall, while septal values remained within the normal range.</p><p>Overall, the CMR findings confirmed acute myocarditis with mildly reduced left ventricular ejection fraction and mild diffuse hypokinesis.</p><p></p><h2 data-id="comments">Comments</h2><h4 data-id="is-there-any-clinically-interesting-aspect-of-the-case-to-discuss-what-difference-did-photon-counting-ct-make-for-the-patient">Is there any clinically interesting aspect of the case to discuss? <br />
What difference did photon-counting CT make for the patient?</h4><p>This case highlights the potential diagnostic value of photon-counting CT in patients presenting with acute chest pain, elevated cardiac biomarkers, and electrocardiographic changes suggestive of acute coronary syndrome.</p><p>The 6-minute delayed-phase acquisition allowed visual assessment of myocardial iodine retention. Delayed-phase spectral reconstruction using monoenergetic plus images and color-coded iodine maps improved visualization of myocardial iodine distribution and enabled myocardial tissue characterization.</p><p>Focal subepicardial to mid-myocardial iodine accumulation indicated abnormal myocardial tissue characteristics. The distribution of delayed iodine enhancement corresponded closely to the edema, late gadolinium enhancement, and elevated CMR-derived ECV values in the affected myocardial segments.</p><p>An important limitation is the additional radiation exposure associated with the delayed-phase of CT imaging. This is particularly relevant in young patients, in whom radiation dose should be carefully justified and minimized.</p><p>Therefore, delayed-phase PCCT acquisitions should not be considered for routine in all patients with suspected myocarditis, but rather reserved for selected cases in which the expected diagnostic benefit outweighs the additional dose, such as when CMR is contraindicated, unavailable, or unlikely to be feasible.</p><p>PCCT could serve as a comprehensive first-line imaging tool in selected patients with suspected myocarditis and possible acute coronary syndrome. Its inherent spectral capabilities, together with its high spatial resolution, allow rapid exclusion of obstructive coronary artery disease while also enabling visual myocardial tissue characterization through delayed-phase spectral imaging, monoenergetic reconstructions, and iodine mapping.</p><p>These capabilities support comprehensive coronary artery evaluation while simultaneously providing additional insights into myocardial tissue characteristics within a single examination.</p><p></p><h2 data-id="examination-protocol">Examination Protocol</h2><p></p><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha.Peak</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Heart</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>QuantumPlus + HD (combined spectral and HighRes)</p></td></tr><tr><td><p><strong>Scan length</strong></p></td><td><p>141 mm</p></td></tr><tr><td><p><strong>Scan direction</strong></p></td><td><p>Cranio-caudal</p></td></tr><tr><td><p><strong>Scan time</strong></p></td><td><p>0.507 s</p></td></tr><tr><td><p><strong>Tube voltage</strong></p></td><td><p>140 kV</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>100</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>CARE Dose4D</p></td></tr><tr><td><p><strong>CTDIvol</strong></p></td><td><p>17.5 mGy</p></td></tr><tr><td><p><strong>DLP</strong></p></td><td><p>245 mGy*cm</p></td></tr><tr><td><p><strong>Rotation time</strong></p></td><td><p>0.25 s</p></td></tr><tr><td><p><strong>Pitch</strong></p></td><td><p>not applicable</p></td></tr><tr><td><p><strong>Slice collimation</strong></p></td><td><p>144 x 0.4 mm</p></td></tr><tr><td><p><strong>Slice width</strong></p></td><td><p>0.4 mm</p></td></tr><tr><td><p><strong>Reconstruction increment</strong></p></td><td><p>0.4 mm</p></td></tr><tr><td><p><strong>Reconstruction kernel</strong></p></td><td><p>Qr44 Q4</p></td></tr><tr><td><p><strong>keV level</strong></p></td><td><p>40</p></td></tr><tr><td><p><strong>Spectral reconstruction</strong></p></td><td><p>Monoenergetic Plus; iodine/water decomposition; iodine maps</p></td></tr><tr><td><p><strong>Heart rate</strong></p></td><td><p>57/min (delayed)</p></td></tr><tr><td><p><strong>Contrast</strong></p></td><td><p>Iomeron 400, 400 mg/mL</p></td></tr><tr><td><p><strong>Volume</strong></p></td><td><p>80 mL + 10mL saline pacer + 30mL saline chaser (for CCTA)</p></td></tr><tr><td><p><strong>Flow rate</strong></p></td><td><p>5 mL/s</p></td></tr><tr><td><p><strong>Start delay</strong></p></td><td><p>Bolus tracking triggered at 92 HU (CCTA), delayed acquisition performed 6 minutes after contrast administration.</p></td></tr></table></div><p></p><h2 data-id="disclaimer">Disclaimer</h2><p>The statements by customers of Siemens Healthineers described herein are based on results that were achieved in the customer’s unique setting. Because there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results.</p><p>The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.</p>]]>
        </description>
    </item>
    <item>
        <title>(2026) Hyska | Time-resolved PCCT estimates post-TAVI pressure gradients</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/534/2026-hyska-time-resolved-pcct-estimates-post-tavi-pressure-gradients</link>
        <pubDate>Mon, 28 Sep 2026 08:03:04 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">534@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 71 post-TAVI PCCT examinations from 63 patients, time-resolved cardiac PCCT enabled calculation of prosthetic-valve hemodynamics from left-ventricular volumetry and direct valve-orifice planimetry. CT-derived mean and maximum transvalvular gradients correlated strongly with echocardiography (ρ = 0.85 for both), while corrected valve area showed a correlation of ρ = 0.73.</p><p></p><p>The most clinically useful parameter was the mean transvalvular gradient (Pmean). Using echocardiographic Pmean ≥20 mmHg as the reference for potential valve dysfunction, PCCT achieved AUC 0.94, sensitivity 88.9%, specificity 88.6%, and overall accuracy 88.7%. The independently derived optimal PCCT cutoff was almost identical at 20.4 mmHg.</p><p></p><p>PCCT-derived Pmean showed much better agreement than Pmax: mean Pmean bias was only 1.6 mmHg, whereas Pmax was systematically higher and showed wider limits of agreement. This suggests that a post-TAVI PCCT already obtained for structural assessment could potentially provide opportunistic functional valve assessment, although the retrospective single-center workflow still requires external validation.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fwww.journalofcardiovascularct.com%2Farticle%2FS1934-5925%2826%2900484-3%2Ffulltext" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/CGFSADE94G8J\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:5318603,&quot;width&quot;:3354,&quot;height&quot;:1877,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FCGFSADE94G8J%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1800,&quot;dateInserted&quot;:&quot;2026-09-28T08:01:31+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FCGFSADE94G8J%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/CGFSADE94G8J/image.png" alt="image.png" height="1877" width="3354" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/CGFSADE94G8J/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/CGFSADE94G8J/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/CGFSADE94G8J/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/CGFSADE94G8J/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/CGFSADE94G8J/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/CGFSADE94G8J/image.png 2000w, https://us.v-cdn.net/6038601/uploads/CGFSADE94G8J/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 1. </strong>Schematic overview of the CT-based workflow for post-TAVI hemodynamic assessment. Time-resolved cardiac CT was used to derive prosthetic valve hemodynamics after TAVI by combining multiphase left-ventricular volumetry, valve orifice area planimetry, quality control for excluding cases with severe mitral regurgitation and hemodynamic modeling of transvalvular flow.</p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Cardiac / post-TAVI prosthetic valve</p></td></tr><tr><td><p><strong>Acquisition mode</strong></p></td><td><p>Quantum HD</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>Retrospectively ECG-gated spiral</p></td></tr><tr><td><p><strong>Tube voltage [kVp]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>60</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>Automatic tube-current modulation; ECG-based modulation at 30–70% RR</p></td></tr><tr><td><p><strong>CTDIvol [mGy]</strong></p></td><td><p>44.1 ± 13.6</p></td></tr><tr><td><p><strong>DLP [mGy·cm]</strong></p></td><td><p>670.0 [476.0–849.5]</p></td></tr><tr><td><p><strong>Effective dose [mSv]</strong></p></td><td><p>17.4 [12.4–22.1]</p></td></tr><tr><td><p><strong>Rotation time [ms]</strong></p></td><td><p>250</p></td></tr><tr><td><p><strong>Detector slice collimation</strong></p></td><td><p>120 × 0.2 mm</p></td></tr><tr><td><p><strong>Temporal reconstruction</strong></p></td><td><p>Full cardiac cycle at 10% RR increments</p></td></tr><tr><td><p><strong>Pressure-curve temporal sampling</strong></p></td><td><p>Resampled to 66 ms</p></td></tr><tr><td><p><strong>Volumetry reconstruction</strong></p></td><td><p>Bv36; 0.8/0.6-mm thickness/increment; </p><p>512 × 512; </p><p>QIR 3</p></td></tr><tr><td><p><strong>Valve-orifice reconstruction</strong></p></td><td><p>BMI-adapted Bv60/Bv64; </p><p>0.2/0.1-mm thickness/increment; </p><p>512 × 512; QIR 4</p></td></tr><tr><td><p><strong>Valve phase</strong></p></td><td><p>Automatically selected best systolic phase</p></td></tr><tr><td><p><strong>Contrast</strong></p></td><td><p>Iodinated contrast, 350–370 mg I/mL</p></td></tr><tr><td><p><strong>Contrast volume</strong></p></td><td><p>75 mL</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>3 mL/s</p></td></tr><tr><td><p><strong>Bolus triggering</strong></p></td><td><p>Ascending aorta</p></td></tr><tr><td><p><strong>Post-processing</strong></p></td><td><p>Multiphase LV volumetry + prosthetic-valve orifice planimetry</p></td></tr><tr><td><p><strong>Hemodynamic model</strong></p></td><td><p>Flow/velocity calculation followed by simplified Bernoulli equation</p></td></tr><tr><td><p><strong>Severe mitral regurgitation exclusion</strong></p></td><td><p>CT-derived mitral regurgitation fraction &gt;40%</p></td></tr></table></div><p> </p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p><strong>71 scans / 63 patients</strong></p></td></tr><tr><td><p><strong>Pmean correlation with TTE</strong></p></td><td><p><strong>ρ = 0.85</strong>, <em>p</em> &lt; 0.001</p></td></tr><tr><td><p><strong>Pmean agreement</strong></p></td><td><p>CT <strong>20.2 [13.4–27.6]</strong> vs TTE <strong>20.0 [16.0–24.5] mmHg</strong>, <em>p</em> = 0.080; </p><p>bias <strong>1.6 mmHg</strong></p></td></tr><tr><td><p><strong>Valve-dysfunction detection</strong></p></td><td><p><strong>AUC 0.94</strong>, sensitivity <strong>88.9%</strong>, specificity <strong>88.6%</strong>, accuracy <strong>88.7%</strong></p></td></tr><tr><td><p><strong>Optimal PCCT Pmean cutoff</strong></p></td><td><p><strong>20.4 mmHg</strong></p></td></tr><tr><td><p><strong>Longitudinal follow-up</strong></p></td><td><p>Pmean change correlated with TTE (<strong>ρ = 0.80</strong>); all <strong>8/8</strong> paired follow-ups concordantly classified around the 20-mmHg threshold</p></td></tr></table></div><p> </p><p><strong>Source:</strong><br />
Hyska S, Osoria-Velasquez J, Hagar MT, et al. <em>Photon-counting detector CT for prediction of valve dysfunction after transcatheter aortic valve implantation: Comparison with echocardiography.</em> <strong>Journal of Cardiovascular Computed Tomography.</strong> Articles in Press. Published September 18, 2026.</p>]]>
        </description>
    </item>
    <item>
        <title>(2023) van der Bie | PCCT for TAVR planning and follow-up</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/518/2023-van-der-bie-pcct-for-tavr-planning-and-follow-up</link>
        <pubDate>Fri, 04 Sep 2026 06:28:26 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">518@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>This early case series illustrates how <strong>UHR PCCT can improve structural heart imaging before and after TAVR</strong>, particularly through sharper depiction of the aortic valve, annulus, coronary arteries, prosthetic valve frames, and vascular access routes. UHR acquisition allows <strong>0.2-mm sections</strong>, compared with 0.4 mm in the regular PCCT mode, helping reduce calcium and metal blooming.</p><p></p><p>In pre-TAVR imaging, sharper reconstruction improved visualization of heavily calcified coronary arteries and <strong>IMAR substantially improved femoral-artery assessment despite bilateral hip prostheses</strong>. Post-TAVR, PCCT depicted hypoattenuating leaflet thickening, valve-in-valve anatomy, and an incompletely expanded left-main stent with an assessable lumen despite substantial surrounding metal and calcium.</p><p></p><p>The spectral capabilities add information beyond spatial resolution: <strong>VMI, virtual noncontrast, and iodine maps</strong> helped characterize leaflet abnormalities and distinguish iodine from calcification. These are promising proof-of-concept applications, but the report is a small case series rather than a comparative diagnostic-accuracy study. </p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fpubs.rsna.org%2Fdoi%2F10.1148%2Fryct.220318" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/KIY54GCOCYGQ\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:474860,&quot;width&quot;:1000,&quot;height&quot;:575,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FKIY54GCOCYGQ%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1730,&quot;dateInserted&quot;:&quot;2026-09-04T06:27:51+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FKIY54GCOCYGQ%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/KIY54GCOCYGQ/image.png" alt="image.png" height="575" width="1000" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/KIY54GCOCYGQ/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/KIY54GCOCYGQ/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/KIY54GCOCYGQ/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/KIY54GCOCYGQ/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/KIY54GCOCYGQ/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/KIY54GCOCYGQ/image.png 2000w, https://us.v-cdn.net/6038601/uploads/KIY54GCOCYGQ/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 2</strong>: Photon-counting detector CT scan for pre–transcatheter aortic valve replacement planning in an 81-year-old female patient (with contrast material). <strong>(A)</strong> Electrocardiogram shows a highly irregular heart rate was present at the time of scanning. <strong>(B)</strong> Contrast-enhanced visualization of the aortic annulus and native aortic valve in the sagittal plane with sharp delineation of the leaflets and a small calcification in the nodule of Arantius (white arrow). <strong>(C)</strong> Ultra-high-resolution image shows the coronary arteries (Bv56 kernel, multiplanar reformatted image). <strong>(D)</strong> Conventional reconstructions at 0.6-mm section thickness (Bv40 kernel) for comparison (multiplanar reformatted image). <strong>(E, F)</strong> Axial reconstructions at the level of the femoral arteries (arrows) without <strong>(E)</strong> and with <strong>(F)</strong> iterative metal artifact reduction (IMAR) reconstruction. QIR = quantitative iterative reconstruction. </p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha, dual-source PCCT</p></td></tr><tr><td><p><strong>Regular detector configuration</strong></p></td><td><p>144 × 0.4 mm</p></td></tr><tr><td><p><strong>UHR detector configuration</strong></p></td><td><p>120 × 0.2 mm</p></td></tr><tr><td><p><strong>UHR section thickness</strong></p></td><td><p>0.2 mm</p></td></tr><tr><td><p><strong>Pre-TAVR cardiac acquisition, Case 2</strong></p></td><td><p>Prospectively ECG-triggered UHR CTA, 15–53% RR</p></td></tr><tr><td><p><strong>Tube voltage, Case 2 [kVp]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>IQ level, Case 2</strong></p></td><td><p>43</p></td></tr><tr><td><p><strong>CTDIvol, Case 2 cardiac [mGy]</strong></p></td><td><p>26.8</p></td></tr><tr><td><p><strong>Access-route acquisition, Case 2</strong></p></td><td><p>High-pitch skull base to groin, 0.4-mm sections</p></td></tr><tr><td><p><strong>Access-route IQ level</strong></p></td><td><p>41</p></td></tr><tr><td><p><strong>Access-route CTDIvol [mGy]</strong></p></td><td><p>2.45</p></td></tr><tr><td><p><strong>Coronary UHR kernel, Case 2</strong></p></td><td><p>Bv56</p></td></tr><tr><td><p><strong>Comparator reconstruction, Case 2</strong></p></td><td><p>Bv40, 0.6-mm sections</p></td></tr><tr><td><p><strong>Metal artifact reduction</strong></p></td><td><p>IMAR for vascular access assessment</p></td></tr><tr><td><p><strong>Post-TAVR acquisition, Case 3</strong></p></td><td><p>120 kV; IQ 50; CTDIvol 15.2 mGy</p></td></tr><tr><td><p><strong>Spectral post-processing, Case 3</strong></p></td><td><p>VMI, virtual noncontrast, iodine map, fused iodine/VNC</p></td></tr><tr><td><p><strong>Post-TAVR acquisition, Case 4</strong></p></td><td><p>Retrospective ECG-gated UHR; 120 kV; IQ 60; CTDIvol 58 mGy</p></td></tr><tr><td><p><strong>Valve-in-valve acquisition, Case 5</strong></p></td><td><p>Full-cycle retrospective ECG-gated UHR; 120 kV; IQ 65; CTDIvol 61.5 mGy</p></td></tr><tr><td><p><strong>Valve-in-valve reconstruction</strong></p></td><td><p>Bv56; QIR 4</p></td></tr><tr><td><p><strong>Ex vivo valve acquisition</strong></p></td><td><p>UHR, 140 kV</p></td></tr><tr><td><p><strong>Ex vivo reconstruction</strong></p></td><td><p>Qr89/Qr76; QIR 4</p></td></tr></table></div><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Spatial resolution</strong></p></td><td><p>UHR PCCT enabled <strong>0.2-mm</strong> sections vs <strong>0.4 mm</strong> in regular PCCT mode</p></td></tr><tr><td><p><strong>Pre-TAVR coronary imaging</strong></p></td><td><p>Bv56 UHR reconstruction reduced calcium blooming compared with 0.6-mm Bv40</p></td></tr><tr><td><p><strong>Access-route assessment</strong></p></td><td><p>IMAR improved femoral-artery visualization despite bilateral hip prostheses</p></td></tr><tr><td><p><strong>Leaflet assessment</strong></p></td><td><p>PCCT demonstrated hypoattenuating leaflet thickening after TAVR and valve-in-valve TAVR</p></td></tr><tr><td><p><strong>Coronary stent assessment</strong></p></td><td><p>Left-main stent lumen remained assessable; incomplete expansion from adjacent calcification was visualized</p></td></tr><tr><td><p><strong>Spectral imaging</strong></p></td><td><p>VMI, VNC, and iodine maps provided additional characterization of valve leaflets and calcification</p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
van der Bie J, Sharma SP, van Straten M, Bos D, Hirsch A, Dijkshoorn ML, Adrichem R, van Mieghem NMDA, Budde RPJ. <em>Photon-counting Detector CT in Patients Pre- and Post-Transcatheter Aortic Valve Replacement.</em> <strong>Radiology: Cardiothoracic Imaging.</strong> 2023;5(2). doi:10.1148/ryct.220318. </p>]]>
        </description>
    </item>
    <item>
        <title>(2023) Turrion Gomollon | VNI PCCT may replace true noncontrast after EVAR</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/517/2023-turrion-gomollon-vni-pcct-may-replace-true-noncontrast-after-evar</link>
        <pubDate>Fri, 04 Sep 2026 06:24:59 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">517@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In <strong>110 patients undergoing EVAR surveillance</strong>, including <strong>41 endoleaks</strong>, the authors compared conventional triphasic PCCT (true noncontrast + arterial + venous) with a biphasic strategy in which <strong>virtual noniodine (VNI) images reconstructed from the venous phase replaced the true noncontrast acquisition</strong>.</p><p></p><p>Endoleak detection was essentially preserved with VNI. Sensitivity was identical for each reader (<strong>0.95 vs 0.95</strong> and <strong>0.88 vs 0.88</strong>), while specificity remained similar; interreader agreement was substantial with both TNC (<strong>α = 0.716</strong>) and VNI (<strong>α = 0.756</strong>). Subjective image quality and noise were also comparable.  </p><p></p><p>Replacing TNC with VNI could have reduced radiation exposure by approximately <strong>38%</strong>. A caveat is imperfect calcium preservation: small aneurysm calcifications were erroneously removed in <strong>15/110 patients (14%)</strong>, although this affected endoleak diagnosis in only <strong>one case</strong>, producing a false-positive interpretation.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fwww.ovid.com%2Fjnls%2Finvestigativeradiology%2Ffulltext%2F10.1097%2Frli.0000000000000993%7Ephoton-counting-detector-ct-angiography-for-endoleak" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/BSYZ2OS2QPFH\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:472432,&quot;width&quot;:1000,&quot;height&quot;:575,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FBSYZ2OS2QPFH%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1729,&quot;dateInserted&quot;:&quot;2026-09-04T06:24:37+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FBSYZ2OS2QPFH%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/BSYZ2OS2QPFH/image.png" alt="image.png" height="575" width="1000" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/BSYZ2OS2QPFH/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/BSYZ2OS2QPFH/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/BSYZ2OS2QPFH/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/BSYZ2OS2QPFH/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/BSYZ2OS2QPFH/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/BSYZ2OS2QPFH/image.png 2000w, https://us.v-cdn.net/6038601/uploads/BSYZ2OS2QPFH/image.png" sizes="100vw" /></a>
    </span>
</span>
<p>Figure 2. Axial CT images at the level of the aortic aneurysm acquired with photon-counting detector CT in a 60-year-old man referred for follow-up imaging after EVAR: (A) true noncontrast images, (B) arterial phase, (C) venous phase with an arrow pointing at the endoleak, and (D) virtual noniodine images reconstructed from venous phase images. </p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Software</strong></p></td><td><p>VA50</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Thoracoabdominal aorta / EVAR surveillance</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>QuantumPlus multienergy</p></td></tr><tr><td><p><strong>Acquisition phases</strong></p></td><td><p>True noncontrast, arterial, venous</p></td></tr><tr><td><p><strong>Tube voltage [kV]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>68</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>CARE Dose4D</p></td></tr><tr><td><p><strong>CTDIvol [mGy]</strong></p></td><td><p>TNC 5.1 ± 1.5; arterial 3.74 ± 1.4; venous 4.65 ± 1.4</p></td></tr><tr><td><p><strong>DLP [mGy·cm]</strong></p></td><td><p>TNC 353.3 ± 108.1; arterial 258.9 ± 88.8; venous 320 ± 100</p></td></tr><tr><td><p><strong>Total dose</strong></p></td><td><p>CTDIvol 13.5 ± 3.9 mGy; DLP 932.2 ± 286 mGy·cm</p></td></tr><tr><td><p><strong>Rotation time [s]</strong></p></td><td><p>0.25</p></td></tr><tr><td><p><strong>Pitch</strong></p></td><td><p>1.2</p></td></tr><tr><td><p><strong>Detector slice collimation</strong></p></td><td><p>144 × 0.4 mm</p></td></tr><tr><td><p><strong>Reconstruction slice thickness / increment [mm]</strong></p></td><td><p>2.0 / 1.6</p></td></tr><tr><td><p><strong>Iterative reconstruction</strong></p></td><td><p>QIR 4</p></td></tr><tr><td><p><strong>TNC reconstruction</strong></p></td><td><p>70-keV VMI, Br36</p></td></tr><tr><td><p><strong>VNI reconstruction</strong></p></td><td><p>70 keV, PureCalcium, Qr36; reconstructed from venous phase</p></td></tr><tr><td><p><strong>Arterial reconstruction</strong></p></td><td><p>55-keV VMI</p></td></tr><tr><td><p><strong>Venous reconstruction</strong></p></td><td><p>60-keV VMI</p></td></tr><tr><td><p><strong>Contrast</strong></p></td><td><p>Iopromide, Ultravist 370 mg I/mL</p></td></tr><tr><td><p><strong>Contrast volume</strong></p></td><td><p>70 mL total</p></td></tr><tr><td><p><strong>Contrast protocol</strong></p></td><td><p>40-mL contrast bolus → 60-mL 1:1 contrast/saline mixture → 20-mL saline chaser</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>4 mL/s</p></td></tr><tr><td><p><strong>Bolus triggering</strong></p></td><td><p>Ascending aorta; 140 HU at 90 kV</p></td></tr><tr><td><p><strong>Arterial phase</strong></p></td><td><p>12 s after trigger threshold</p></td></tr><tr><td><p><strong>Venous phase</strong></p></td><td><p>70 s after trigger threshold</p></td></tr></table></div><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p><strong>110 patients; 41 endoleaks (37%)</strong></p></td></tr><tr><td><p><strong>Reader 1 sensitivity / specificity</strong></p></td><td><p>TNC <strong>0.95 / 0.84</strong> vs VNI <strong>0.95 / 0.86</strong></p></td></tr><tr><td><p><strong>Reader 2 sensitivity / specificity</strong></p></td><td><p>TNC <strong>0.88 / 0.98</strong> vs VNI <strong>0.88 / 0.94</strong></p></td></tr><tr><td><p><strong>Interreader agreement</strong></p></td><td><p>TNC <strong>α = 0.716</strong>; VNI <strong>α = 0.756</strong></p></td></tr><tr><td><p><strong>Subjective image quality / noise</strong></p></td><td><p>Both <strong>4 [IQR 4–5]</strong>; no significant difference</p></td></tr><tr><td><p><strong>Potential dose reduction</strong></p></td><td><p><strong>38%</strong> by eliminating the TNC acquisition</p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
Turrion Gomollon AM, Mergen V, Sartoretti T, Polacin M, Nakhostin D, Puippe G, Alkadhi H, Euler A. <em>Photon-Counting Detector CT Angiography for Endoleak Detection After Endovascular Aortic Repair: Triphasic CT With True Noncontrast Versus Biphasic CT With Virtual Noniodine Imaging.</em> <strong>Investigative Radiology.</strong> 2023;58(11):816–821. doi:10.1097/RLI.0000000000000993.</p>]]>
        </description>
    </item>
    <item>
        <title>(2024) Qin | Improvement of coronary stent visualization using UHR PCCT</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/516/2024-qin-improvement-of-coronary-stent-visualization-using-uhr-pcct</link>
        <pubDate>Fri, 04 Sep 2026 06:20:43 +0000</pubDate>
        <category>Scientific publications</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">516@/zh/discussions</guid>
        <description><![CDATA[<p></p><div><div><p>In 69 patients with 131 coronary stents, UHR PCCT with 0.2-mm slices significantly improved in-stent lumen visualization and reduced blooming artifacts compared with standard-resolution 0.6-mm reconstruction.</p><p></p><p>Among the evaluated reconstruction kernels, Bv72 provided the best overall performance, improving visualization of the stent lumen and struts while maintaining sufficient image quality for assessment.</p><p></p><p>The improved spatial resolution translated into better diagnostic performance: accuracy for detecting in-stent restenosis increased from 78.3% with standard-resolution PCCT to 88.0% with UHR-Bv72.</p><p></p><p>Clinical takeaway: UHR PCCT can mitigate blooming from metallic stent struts and may improve the reliability of non-invasive coronary stent assessment, particularly when combined with an optimized sharp reconstruction kernel.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00330-024-10760-1" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><p><strong>Source:</strong> Qin L, <em>et al.</em> <em>Improvement of coronary stent visualization using ultra-high-resolution photon-counting detector CT.</em> 2024.</p>]]>
        </description>
    </item>
    <item>
        <title>(2026) Kabakus | Is nitroglycerin still necessary for CCTA in the era of PCCT?</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/514/2026-kabakus-is-nitroglycerin-still-necessary-for-ccta-in-the-era-of-pcct</link>
        <pubDate>Thu, 03 Sep 2026 11:07:46 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">514@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 124 patients with CCTA and invasive coronary angiography (ICA) within 30 days, diagnostic performance of PCCT CCTA was similar with and without sublingual nitroglycerin. Per-patient sensitivity was 90.3% vs 90.9%, and NPV was 86.4% vs 88.9%, with no significant differences between groups.</p><p><br />
The non-nitroglycerin group was numerically better for several diagnostic metrics—specificity 80.0% vs 63.3%, PPV 83.3% vs 71.8%, and accuracy 85.7% vs 77.0%—although none reached statistical significance. Likewise, no significant differences were found across LAD, LCx, or RCA analyses, so the findings remain hypothesis-generating rather than practice-changing.</p><p><br />
Nitroglycerin increased left-main attenuation (634 ± 169 vs 546 ± 147 HU, p = 0.029) but did not improve SNR or CNR. The authors also raise the possibility that vasodilation of healthy reference segments may exaggerate percentage stenosis relative to diseased segments, potentially contributing to false-positive CCTA findings.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS1934592526004740" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/9NJFQUXN7ZFD\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:312399,&quot;width&quot;:713,&quot;height&quot;:507,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F9NJFQUXN7ZFD%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1728,&quot;dateInserted&quot;:&quot;2026-09-03T11:06:13+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F9NJFQUXN7ZFD%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/9NJFQUXN7ZFD/image.png" alt="image.png" height="507" width="713" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/9NJFQUXN7ZFD/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/9NJFQUXN7ZFD/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/9NJFQUXN7ZFD/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/9NJFQUXN7ZFD/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/9NJFQUXN7ZFD/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/9NJFQUXN7ZFD/image.png 2000w, https://us.v-cdn.net/6038601/uploads/9NJFQUXN7ZFD/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 3. </strong>Representative case demonstrating potential nitroglycerin-related overestimation of coronary stenosis severity. A 73-year-old man presenting with chest pain underwent photon-counting CCTA following administration of 0.4 mg sublingual nitroglycerin. (A) Curved multiplanar reformatted CCTA image demonstrates a proximal coronary artery diameter of 3.5 mm, a stenotic segment diameter of 1.8 mm, and a distal reference diameter of 3.0 mm. Based on CCTA findings, the lesion was classified as moderate stenosis (CAD-RADS 3, obstructive disease). (B) Invasive coronary angiography demonstrated slightly smaller reference vessel diameters and a slightly larger residual lumen at the stenotic segment, with measurements of 3.3 mm proximally, 1.9 mm at the stenosis, and 2.7 mm distally. Consequently, the lesion was classified as mild stenosis (non-obstructive disease) by invasive coronary angiography. The discrepancy is likely attributable to nitroglycerin-induced vasodilation of adjacent healthy coronary segments, resulting in approximately 10% enlargement of the reference vessel diameter without substantial dilation of the diseased segment. This differential vasodilatory response increases the apparent percentage stenosis on CCTA and may contribute to overestimation of stenosis severity.</p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Coronary arteries / CCTA</p></td></tr><tr><td><p><strong>Acquisition mode</strong></p></td><td><p>PCCT CCTA</p></td></tr><tr><td><p><strong>Tube voltage [kV]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>64</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>Automated tube current modulation</p></td></tr><tr><td><p><strong>Rotation time [s]</strong></p></td><td><p>0.25</p></td></tr><tr><td><p><strong>Detector slice collimation</strong></p></td><td><p>120 × 0.4 mm</p></td></tr><tr><td><p><strong>Prospective ECG acquisition</strong></p></td><td><p>HR &lt;75 bpm with regular rhythm; acquisition window centered at 60–80% of RR</p></td></tr><tr><td><p><strong>Retrospective ECG acquisition</strong></p></td><td><p>HR &gt;75 bpm or irregular rhythm; full radiation at 30–50% of RR, reduced to 10% during remainder</p></td></tr><tr><td><p><strong>Reconstruction slice thickness [mm]</strong></p></td><td><p>0.4</p></td></tr><tr><td><p><strong>Reconstruction increment [mm]</strong></p></td><td><p>0.3</p></td></tr><tr><td><p><strong>Matrix</strong></p></td><td><p>512 × 512</p></td></tr><tr><td><p><strong>FOV</strong></p></td><td><p>Dedicated cardiac FOV optimized for coronary assessment</p></td></tr><tr><td><p><strong>Kernel</strong></p></td><td><p>Bv44 smooth and Bv60 sharp</p></td></tr><tr><td><p><strong>Iterative reconstruction</strong></p></td><td><p>QIR 3</p></td></tr><tr><td><p><strong>Contrast</strong></p></td><td><p>Iohexol, Omnipaque 350</p></td></tr><tr><td><p><strong>Contrast volume</strong></p></td><td><p>BMI &lt;25: 50–60 mL; BMI 25–30: 60–70 mL; BMI &gt;30: 70–80 mL</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>5 mL/s</p></td></tr><tr><td><p><strong>Bolus triggering</strong></p></td><td><p>Descending aorta; monitoring begins 8 s after injection onset; 100-HU threshold</p></td></tr><tr><td><p><strong>Post-trigger delay</strong></p></td><td><p>6 s</p></td></tr><tr><td><p><strong>Mixed bolus</strong></p></td><td><p>30 mL of 50% contrast/saline at 5 mL/s</p></td></tr><tr><td><p><strong>Saline chaser</strong></p></td><td><p>30 mL at 5 mL/s</p></td></tr><tr><td><p><strong>Venous access</strong></p></td><td><p>18-gauge IV</p></td></tr><tr><td><p><strong>Heart-rate control</strong></p></td><td><p>IV metoprolol 5-mg increments every 5 min, maximum 25 mg; target HR &lt;75 bpm</p></td></tr><tr><td><p><strong>Nitroglycerin comparison</strong></p></td><td><p>0.4 mg sublingual nitroglycerin vs no nitroglycerin</p></td></tr></table></div><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p><strong>124 patients</strong>: 61 nitroglycerin / 63 no nitroglycerin</p></td></tr><tr><td><p><strong>Sensitivity</strong></p></td><td><p><strong>90.3% vs 90.9%</strong>, <em>p</em> = 0.940</p></td></tr><tr><td><p><strong>Specificity</strong></p></td><td><p><strong>63.3% vs 80.0%</strong>, <em>p</em> = 0.160</p></td></tr><tr><td><p><strong>PPV / NPV</strong></p></td><td><p><strong>71.8% / 86.4% vs 83.3% / 88.9%</strong></p></td></tr><tr><td><p><strong>Overall accuracy</strong></p></td><td><p><strong>77.0% vs 85.7%</strong>, <em>p</em> = 0.220</p></td></tr><tr><td><p><strong>Objective image quality</strong></p></td><td><p>LM attenuation higher with nitroglycerin (<strong>634 vs 546 HU</strong>, <em>p</em> = 0.029), but <strong>SNR and CNR unchanged</strong></p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
Kabakus IM, Maisuria DM, Chamberlin JH, Mencken IL, Lopez Rodriguez CG, Sagatelian MM, Burt JR, Baruah D. <em>Is nitroglycerin still necessary for coronary CT angiography in the era of photon-counting CT?</em> <strong>Journal of Cardiovascular Computed Tomography.</strong> 2026. In Press, Corrected Proof. Available online August 22, 2026. doi:10.1016/j.jcct.2026.08.007.</p>]]>
        </description>
    </item>
    <item>
        <title>(2023) Vattay | VMI energy substantially alters PCCT coronary plaque quantification</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/509/2023-vattay-vmi-energy-substantially-alters-pcct-coronary-plaque-quantification</link>
        <pubDate>Wed, 02 Sep 2026 11:20:19 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">509@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 51 patients with 51 coronary plaques, PCCT VMI energy had a substantial effect on measured plaque attenuation and consequently on quantitative plaque composition when fixed HU thresholds were used. Mean plaque attenuation fell progressively from 723 ± 501 HU at 40 keV to 120 ± 112 HU at 180 keV, while 70-keV VMI most closely reproduced the 120-kVp T3D reference attenuation.</p><p><br />
The effect differed by plaque component. With the primary threshold method, calcified plaque volume decreased from 138.7 ± 126.4 mm³ at 40 keV to 38.5 ± 64.6 mm³ at 180 keV, whereas low-attenuation plaque increased from 22.8 ± 24.9 to 96.0 ± 76.3 mm³. Thus, a plaque can appear quantitatively very different solely because the VMI energy changes.</p><p><br />
Low-keV images provided the highest CNR and SNR but also more noise. The key practical implication is that fixed plaque-attenuation thresholds developed for conventional images should not simply be transferred across PCCT VMI energies; standardized energy-specific thresholds or normalization strategies are needed for reproducible plaque quantification.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00330-023-09876-7" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/O5MMBK8YZ8FO\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:1232263,&quot;width&quot;:2000,&quot;height&quot;:1150,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FO5MMBK8YZ8FO%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1710,&quot;dateInserted&quot;:&quot;2026-09-02T11:19:17+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FO5MMBK8YZ8FO%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/O5MMBK8YZ8FO/image.png" alt="image.png" height="1150" width="2000" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/O5MMBK8YZ8FO/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/O5MMBK8YZ8FO/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/O5MMBK8YZ8FO/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/O5MMBK8YZ8FO/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/O5MMBK8YZ8FO/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/O5MMBK8YZ8FO/image.png 2000w, https://us.v-cdn.net/6038601/uploads/O5MMBK8YZ8FO/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure1.</strong> Representative CTA images of coronary plaques reconstructed in T3D and different VMI energy levels (40, 70, 120, and 180 keV). Quantitative plaque analyses of a partially calcified-predominantly non-calcified (panel A) and partially calcified-predominantly calcified (panel B) plaque are shown in T3D and different VMI reconstructions at 40, 70, 120, and 180 keV levels. The red line illustrates the border of the vessel wall and the orange line illustrates the lumen border segmented on T3D images. Corresponding cross-sectional images are also depicted at the point of the maximal narrowing of the lesion. The same window setting was applied for all represented images: window: 800; level: 250. Abbreviations: CP, calcified plaque; HU, Hounsfield unit; LAP, low-attenuation non-calcified plaque; NCP, non-calcified plaque.</p><p></p><h2 data-id="protocol">Protocol</h2><p></p><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Coronary CTA</p></td></tr><tr><td><p><strong>Acquisition mode</strong></p></td><td><p>ECG-triggered PCCT</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>TurboFlash high-pitch, sequential, or helical depending on heart rate/rhythm</p></td></tr><tr><td><p><strong>Tube voltage [kV]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>80</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>Automatic tube current modulation</p></td></tr><tr><td><p><strong>Rotation time [s]</strong></p></td><td><p>0.25</p></td></tr><tr><td><p><strong>Detector configuration</strong></p></td><td><p>144 × 0.4 mm</p></td></tr><tr><td><p><strong>Slice thickness [mm]</strong></p></td><td><p>0.4</p></td></tr><tr><td><p><strong>Reconstruction increment [mm]</strong></p></td><td><p>0.4</p></td></tr><tr><td><p><strong>Matrix</strong></p></td><td><p>512 × 512</p></td></tr><tr><td><p><strong>Kernel</strong></p></td><td><p>Bv40</p></td></tr><tr><td><p><strong>Iterative reconstruction</strong></p></td><td><p>QIR 2</p></td></tr><tr><td><p><strong>Reference reconstruction</strong></p></td><td><p>120-kVp polychromatic T3D</p></td></tr><tr><td><p><strong>VMI energies</strong></p></td><td><p>40–180 keV in 10-keV increments</p></td></tr><tr><td><p><strong>ECG phase</strong></p></td><td><p>Diastolic 65–85% RR or systolic 200–400 ms depending on heart rate</p></td></tr><tr><td><p><strong>Contrast volume</strong></p></td><td><p>70–80 mL</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>4.5–5.0 mL/s</p></td></tr><tr><td><p><strong>Contrast protocol</strong></p></td><td><p>Four-phasic</p></td></tr><tr><td><p><strong>Heart-rate control</strong></p></td><td><p>IV beta-blocker if HR &gt;65 bpm</p></td></tr><tr><td><p><strong>Vasodilation</strong></p></td><td><p>0.8 mg sublingual nitroglycerin if systolic BP &gt;100 mmHg</p></td></tr><tr><td><p><strong>Plaque analysis software</strong></p></td><td><p>AutoPlaque 2.5</p></td></tr><tr><td><p><strong>Primary plaque thresholds</strong></p></td><td><p>LAP −100 to 30 HU; NCP 30–350 HU; CP &gt;350 HU</p></td></tr></table></div><p></p><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p><strong>51 patients / 51 plaques</strong></p></td></tr><tr><td><p><strong>Plaque attenuation</strong></p></td><td><p><strong>723 ± 501 HU at 40 keV → 120 ± 112 HU at 180 keV</strong></p></td></tr><tr><td><p><strong>CNR</strong></p></td><td><p>Highest at <strong>40 keV: 22.1 ± 5.6</strong>; 70 keV similar to T3D</p></td></tr><tr><td><p><strong>Calcified plaque volume</strong></p></td><td><p><strong>138.7 ± 126.4 mm³ at 40 keV → 38.5 ± 64.6 mm³ at 180 keV</strong></p></td></tr><tr><td><p><strong>Low-attenuation plaque volume</strong></p></td><td><p><strong>22.8 ± 24.9 mm³ at 40 keV → 96.0 ± 76.3 mm³ at 180 keV</strong></p></td></tr><tr><td><p><strong>Closest VMI to T3D</strong></p></td><td><p><strong>70 keV</strong> for overall attenuation/CP; <strong>50 keV</strong> for LAP with primary thresholds</p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
Vattay B, Szilveszter B, Boussoussou M, Vecsey-Nagy M, Lin A, Konkoly G, Kubovje A, Schwarz F, Merkely B, Maurovich-Horvat P, Williams MC, Dey D, Kolossváry M. <em>Impact of virtual monoenergetic levels on coronary plaque volume components using photon-counting computed tomography.</em> <strong>European Radiology.</strong> 2023;33:8528–8539. doi:10.1007/s00330-023-09876-7.</p>]]>
        </description>
    </item>
    <item>
        <title>(2026) Tateishi | PCCT depicts a ventricular tachycardia substrate</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/507/2026-tateishi-pcct-depicts-a-ventricular-tachycardia-substrate</link>
        <pubDate>Tue, 01 Sep 2026 15:01:37 +0000</pubDate>
        <category>Case reports</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">507@/zh/discussions</guid>
        <description><![CDATA[<p>The case report hase been published by:</p><p>Tateishi, R, Nishimura, T, Tao, S. et al. Photon-Counting Detector Computed Tomography Depicts a Ventricular Tachycardia Substrate: Periaortic Septal Intramural Late Iodine Enhancement. <em>J Am Coll Cardiol Case Rep. </em>2026 Apr, 31 (15) . <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.jaccas.2026.107250" rel="nofollow noopener ugc">https://doi.org/10.1016/j.jaccas.2026.107250</a></p><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fwww.jacc.org%2Fdoi%2Fepdf%2F10.1016%2Fj.jaccas.2026.107250" rel="nofollow noopener ugc" role="button">Check pdf</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/7M2O396VPAQ2\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:5100393,&quot;width&quot;:3249,&quot;height&quot;:2003,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F7M2O396VPAQ2%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1708,&quot;dateInserted&quot;:&quot;2026-09-01T15:00:12+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F7M2O396VPAQ2%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/7M2O396VPAQ2/image.png" alt="image.png" height="2003" width="3249" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/7M2O396VPAQ2/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/7M2O396VPAQ2/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/7M2O396VPAQ2/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/7M2O396VPAQ2/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/7M2O396VPAQ2/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/7M2O396VPAQ2/image.png 2000w, https://us.v-cdn.net/6038601/uploads/7M2O396VPAQ2/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Visual Summary</strong> Spatial Relationship Between LIE on PCD-CT and Arrhythmogenic Substrate(A) Preprocedural photon-counting detector computed tomography image and three-dimensional visualization using ADAS 3D software. The red arrow indicates late iodine enhancement. (B) Isochronal late activation map. Lines of conduction block with split potentials (yellow arrows) were observed in the RVOT and periaortic septal region of the LVOT, spatially corresponding to the edge of the late iodine enhancement area. Ao = aorta; LIE = late iodine enhancement; LV = left ventricle; LVOT = left ventricular outflow tract; RV = right ventricle; RVOT = right ventricular outflow tract; PA = pulmonary artery; PCD-CT = photon-counting detector computed tomography.</p><p></p><h3 data-id="background">Background</h3><p>Recent studies have demonstrated that delayed enhancement using contrast-enhanced computed tomography corresponds with late gadolinium enhancement on cardiac magnetic resonance imaging. However, few studies have evaluated scar-related ventricular tachycardia (VT) substrates using high-resolution photon-counting detector computed tomography (PCCT).</p><h3 data-id="case-summary">Case Summary</h3><p>A 49-year-old man with cardiac sarcoidosis underwent catheter ablation of monomorphic VT. Preoperative iodine mapping on PCD-CT showed late iodine enhancement (LIE) localized to the septal region between the periaortic region and right ventricular outflow tract. Electroanatomic mapping revealed a localized abnormal voltage area and line of conduction block with split potentials colocalized with the LIE. Radiofrequency ablation was performed from both the right and left ventricular outflow tracts and successfully eliminated the VT inducibility. No ICD shocks have occurred after the procedure.</p><h3 data-id="discussion">Discussion</h3><p>PCD-CT provides improved signal detection and superior spatial resolution, enabling visualization of VT substrates in anatomically challenging regions. In patients who are contraindicated for cardiac magnetic resonance imaging, PCD-CT serves as a valuable alternative imaging modality.</p><p></p><h2 data-id="take-home-messages">Take-Home Messages</h2><p>The higher spatial resolution of PCD-CT enables a more precise detection of periaortic substrates, whereas detecting late gadolinium enhancement on cardiac magnetic resonance imaging is challenging given a thin myocardium and anatomical complexity.<strong>•</strong>Because PCD-CT does not have the same restrictions as cardiac magnetic resonance imaging, it can be used in patients with non–MRI-conditional implantable cardioverter-defibrillators to accurately identify and locate ventricular tachycardia substrates.</p>]]>
        </description>
    </item>
    <item>
        <title>(2024) Hagar | UHR PCCT accurately evaluates coronary stent patency</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/504/2024-hagar-uhr-pcct-accurately-evaluates-coronary-stent-patency</link>
        <pubDate>Fri, 28 Aug 2026 11:00:01 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">504@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 18 patients with 44 coronary stents, ultra-high-resolution (UHR) PCCT angiography achieved high diagnostic accuracy for detecting ≥50% in-stent stenosis compared with invasive coronary angiography (ICA). Both readers identified all 5 stenotic stents, yielding 100% sensitivity.</p><p></p><p>Specificity and overall accuracy were 92.3% and 93.2% for reader 1 and 87.2% and 88.6% for reader 2. Most importantly, the negative predictive value was 100% for both readers, supporting UHR PCCT as a strong noninvasive technique for ruling out clinically relevant in-stent restenosis.</p><p></p><p>Stent-lumen image quality was generally good to excellent, with only 3/44 stents considered nondiagnostic by both readers. Despite residual stent blooming of approximately 38–40%, the 0.2-mm reconstruction with a sharp Bv60 kernel provided sufficient lumen visualization for reliable clinical assessment in more than 90% of stents.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00330-023-10516-3" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/TFTINO5MWQAV\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:2596207,&quot;width&quot;:1990,&quot;height&quot;:1090,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FTFTINO5MWQAV%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1681,&quot;dateInserted&quot;:&quot;2026-08-28T10:58:38+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FTFTINO5MWQAV%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/TFTINO5MWQAV/image.png" alt="image.png" height="1090" width="1990" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/TFTINO5MWQAV/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/TFTINO5MWQAV/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/TFTINO5MWQAV/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/TFTINO5MWQAV/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/TFTINO5MWQAV/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/TFTINO5MWQAV/image.png 2000w, https://us.v-cdn.net/6038601/uploads/TFTINO5MWQAV/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 4. </strong>Ultra-high-resolution photon-counting detector CT angiography (PCD-CTA) of the heart of a 69-year-old male patient with severe aortic valve stenosis and a history of coronary stent implantation in the distal left main and proximal left anterior descending artery (LAD) (arrowhead in <strong>A</strong>, <strong>B</strong>, and <strong>C</strong>). <strong>A</strong> Three-dimensional cinematic rendering of the heart, showing the stent in the LAD. <strong>B</strong> Curved multiplanar reformation showing the absence of in-stent stenosis. The stent was rated as “excellent”—Likert 1 by one reader—and as “good”—Likert 2 by the other reader. <strong>C</strong> Invasive coronary angiography at caudal 30° view, verifying stent patency</p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Software</strong></p></td><td><p>syngo CT VA50; syngo.via VB60</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Coronary arteries as part of TAVI-CT</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>Ultra-high resolution</p></td></tr><tr><td><p><strong>Acquisition mode</strong></p></td><td><p>ECG-synchronized UHR PCCT angiography</p></td></tr><tr><td><p><strong>Detector slice collimation</strong></p></td><td><p>120 × 0.2 mm</p></td></tr><tr><td><p><strong>Matrix</strong></p></td><td><p>1024 × 1024</p></td></tr><tr><td><p><strong>Field of view [mm]</strong></p></td><td><p>180 × 180</p></td></tr><tr><td><p><strong>Slice thickness [mm]</strong></p></td><td><p>0.2</p></td></tr><tr><td><p><strong>Reconstruction increment [mm]</strong></p></td><td><p>0.1</p></td></tr><tr><td><p><strong>Reconstruction kernel</strong></p></td><td><p>Bv60</p></td></tr><tr><td><p><strong>Iterative reconstruction</strong></p></td><td><p>QIR 3</p></td></tr><tr><td><p><strong>ECG reconstruction</strong></p></td><td><p>Automatically selected best-systolic and best-diastolic phases plus multiphase data</p></td></tr><tr><td><p><strong>Contrast agent</strong></p></td><td><p>Iopromide, Ultravist 370</p></td></tr><tr><td><p><strong>Contrast protocol</strong></p></td><td><p>70 mL contrast followed by 40 mL isotonic saline + 30 mL contrast mixture</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>5.0 mL/s</p></td></tr><tr><td><p><strong>Bolus triggering</strong></p></td><td><p>Aortic root, 130-HU threshold</p></td></tr><tr><td><p><strong>Trigger delay</strong></p></td><td><p>10 s</p></td></tr><tr><td><p><strong>Patient preparation</strong></p></td><td><p>No nitroglycerin or beta-blockers administered</p></td></tr></table></div><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p><strong>18 patients / 44 coronary stents</strong></p></td></tr><tr><td><p><strong>In-stent stenosis prevalence</strong></p></td><td><p><strong>5/44 (11.4%)</strong></p></td></tr><tr><td><p><strong>Sensitivity</strong></p></td><td><p><strong>100%</strong> for both readers</p></td></tr><tr><td><p><strong>Specificity</strong></p></td><td><p><strong>92.3%</strong> reader 1; <strong>87.2%</strong> reader 2</p></td></tr><tr><td><p><strong>Diagnostic accuracy</strong></p></td><td><p><strong>93.2%</strong> reader 1; <strong>88.6%</strong> reader 2</p></td></tr><tr><td><p><strong>Negative predictive value</strong></p></td><td><p><strong>100%</strong> for both readers</p></td></tr><tr><td><p><strong>Inter-reader agreement</strong></p></td><td><p><strong>90.1%; κ = 0.72</strong></p></td></tr><tr><td><p><strong>Stent blooming</strong></p></td><td><p><strong>37.9 ± 9.6%</strong> and <strong>40.1 ± 8.9%</strong></p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
Hagar MT, Soschynski M, Saffar R, Molina-Fuentes MF, Weiss J, Rau A, Schuppert C, Ruile P, Faby S, Schibilsky D, von zur Muehlen C, Schlett CL, Bamberg F, Krauss T. <em>Ultra-high-resolution photon-counting detector CT in evaluating coronary stent patency: a comparison to invasive coronary angiography.</em> <strong>European Radiology.</strong> 2024;34:4273–4283. doi:10.1007/s00330-023-10516-3.</p>]]>
        </description>
    </item>
    <item>
        <title>(2024) Haag | PURE Calcium PCCT may replace true noncontrast calcium scoring</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/503/2024-haag-pure-calcium-pcct-may-replace-true-noncontrast-calcium-scoring</link>
        <pubDate>Fri, 28 Aug 2026 10:53:33 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">503@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 170 patients, coronary artery calcium scores derived from PCCT PureCalcium virtual noncontrast images showed excellent correlation with true noncontrast (TNC) calcium scoring (ICC 0.98). Median Agatston scores were not significantly different: 4.8 vs 2.7, respectively (p = 0.99).</p><p></p><p>High correlation did not translate into complete interchangeability. PureCalcium correctly classified 125/170 patients (74%) into CAD-RADS plaque-burden categories, with excellent categorical agreement (κ = 0.88), but discrepancies were concentrated around the clinically important P0/P1 boundary. </p><p></p><p>Eliminating the dedicated TNC acquisition could reduce total cardiac CT radiation exposure by approximately 20%, since the TNC scan contributed 19.7% ± 8.8% of total examination dose. PureCalcium therefore shows considerable potential for single-scan CCTA plus calcium assessment, although caution remains necessary in patients with very low calcium burden.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fpubs.rsna.org%2Fdoi%2F10.1148%2Fradiol.230545" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/K3UZYL4QFW6F\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:191100,&quot;width&quot;:1000,&quot;height&quot;:575,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FK3UZYL4QFW6F%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1680,&quot;dateInserted&quot;:&quot;2026-08-28T10:52:37+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FK3UZYL4QFW6F%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/K3UZYL4QFW6F/image.png" alt="image.png" height="575" width="1000" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/K3UZYL4QFW6F/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/K3UZYL4QFW6F/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/K3UZYL4QFW6F/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/K3UZYL4QFW6F/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/K3UZYL4QFW6F/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/K3UZYL4QFW6F/image.png 2000w, https://us.v-cdn.net/6038601/uploads/K3UZYL4QFW6F/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 2</strong>. Representative images of coronary artery calcifications in true noncontrast coronary artery calcium scoring (CACS) (left column), PureCalcium images from coronary CT angiography (CCTA) (middle column), and contrast-enhanced CCTA (right column). All patients underwent CCTA for evaluation of coronary artery disease, with reconstruction in the axial orientation. <strong>(A)</strong> Images in a 47-year-old female patient with no coronary artery calcifications, P0 in the Coronary Artery Disease Reporting and Data System, or CAD-RADS 2.0. <strong>(B)</strong> Images in a 70-year-old male patient with mild coronary artery calcifications, P1 in CAD-RADS 2.0. <strong>(C)</strong> Images in a 72-year-old female patient with moderate coronary artery calcifications, P2 in CAD-RADS 2.0. <strong>(D)</strong> Images in a 65-year-old male patient with severe coronary artery calcifications, P3 in CAD-RADS 2.0. PureCalcium is a customized algorithm for virtual noncontrast image reconstruction derived from photon-counting CCTA specifically for the purpose of CACS. </p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha, VA50</p></td></tr><tr><td><p><strong>Software</strong></p></td><td><p>syngo.via VB60</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Coronary arteries</p></td></tr><tr><td><p><strong>TNC scan mode</strong></p></td><td><p>High-pitch</p></td></tr><tr><td><p><strong>CCTA scan mode</strong></p></td><td><p>Flash, sequential, or spiral depending on heart rate/rhythm</p></td></tr><tr><td><p><strong>Acquisition mode</strong></p></td><td><p>Standard-resolution PCCT</p></td></tr><tr><td><p><strong>Tube voltage [kV]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>100</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>Automatic tube current modulation</p></td></tr><tr><td><p><strong>Matrix</strong></p></td><td><p>512 × 512</p></td></tr><tr><td><p><strong>TNC slice thickness / increment [mm]</strong></p></td><td><p>3.0 / 1.5</p></td></tr><tr><td><p><strong>CCTA slice thickness / increment [mm]</strong></p></td><td><p>0.4 / 0.2</p></td></tr><tr><td><p><strong>TNC kernel</strong></p></td><td><p>Qr36</p></td></tr><tr><td><p><strong>TNC iterative reconstruction</strong></p></td><td><p>None</p></td></tr><tr><td><p><strong>TNC reconstruction energy</strong></p></td><td><p>70 keV</p></td></tr><tr><td><p><strong>PureCalcium slice thickness / increment [mm]</strong></p></td><td><p>2.0 / 1.5</p></td></tr><tr><td><p><strong>PureCalcium kernel</strong></p></td><td><p>Qr40</p></td></tr><tr><td><p><strong>PureCalcium iterative reconstruction</strong></p></td><td><p>QIR 3</p></td></tr><tr><td><p><strong>Calcium scoring thickness</strong></p></td><td><p>Automatic resampling to 1.5 mm</p></td></tr><tr><td><p><strong>Calcium threshold</strong></p></td><td><p>130 HU; minimum area 0.5 mm²</p></td></tr><tr><td><p><strong>Contrast agent</strong></p></td><td><p>Iohexol, Accupaque 300</p></td></tr><tr><td><p><strong>Contrast volume</strong></p></td><td><p>50–65 mL</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>4 mL/s</p></td></tr><tr><td><p><strong>Contrast timing</strong></p></td><td><p>Test bolus</p></td></tr><tr><td><p><strong>Heart-rate control</strong></p></td><td><p>Up to 15 mg IV metoprolol if required</p></td></tr><tr><td><p><strong>Vasodilation</strong></p></td><td><p>0.4 mg sublingual nitroglycerin if not contraindicated</p></td></tr></table></div><p></p><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p><strong>170 patients</strong>; 111 with CACS &gt;0</p></td></tr><tr><td><p><strong>Median Agatston score</strong></p></td><td><p>TNC <strong>4.8</strong> vs PureCalcium <strong>2.7</strong>, <em>p</em> = 0.99</p></td></tr><tr><td><p><strong>Score correlation</strong></p></td><td><p><strong>ICC 0.98</strong> (95% CI 0.97–0.99)</p></td></tr><tr><td><p><strong>Plaque-burden classification</strong></p></td><td><p><strong>125/170 (74%)</strong> correctly classified; κ = <strong>0.88</strong></p></td></tr><tr><td><p><strong>P0/P1 discrepancies</strong></p></td><td><p>20 patients classified P1 instead of P0; 14 classified P0 instead of P1</p></td></tr><tr><td><p><strong>Radiation contribution of TNC</strong></p></td><td><p>DLP <strong>32.5 ± 11.5 mGy·cm</strong>; <strong>19.7% ± 8.8%</strong> of total examination dose</p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
Haag NP, Michael AE, Lennartz S, Panknin C, Niehoff JH, Borggrefe J, Shahzadi I, Zwanenburg A, Kroeger JR. <em>Coronary Artery Calcium Scoring Using Virtual Versus True Noncontrast Images From Photon-Counting Coronary CT Angiography.</em> <strong>Radiology.</strong> 2024;310(3). doi:10.1148/radiol.230545.</p>]]>
        </description>
    </item>
    <item>
        <title>(2024) Gnasso | Optimized PCCT reconstruction improves myocardial ECV accuracy</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/502/2024-gnasso-optimized-pcct-reconstruction-improves-myocardial-ecv-accuracy</link>
        <pubDate>Fri, 28 Aug 2026 10:48:54 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">502@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 27 patients undergoing same-day PCCT and cardiac MRI, myocardial extracellular volume (ECV) measurements remained robust across a wide range of reconstruction settings, but reconstruction choices meaningfully affected agreement with MRI.</p><p></p><p>The greatest improvement came from combining thin slices with low-keV VMI, rather than from changing iterative reconstruction strength alone. Slice thickness was a particularly important determinant of ECV accuracy. Reconstruction at 0.4/0.3 mm thickness/increment achieved the highest agreement with MRI (CCC ≈ 0.94) and substantially reduced bias compared with thicker reconstructions, likely by limiting partial-volume averaging within the myocardium.</p><p></p><p>The optimal combination was QIR 4, 0.4-mm slices with 0.3-mm increment, and 45-keV VMI. Compared with the literature-standard reconstruction of QIR 3, 1.5 mm, and 65 keV, this reduced mean ECV bias by 63% and increased concordance with MRI by 6%, bringing PCCT-derived ECV substantially closer to the MRI reference.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1186%2Fs41747-024-00469-7" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/KS1C1846OL3N\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:1246377,&quot;width&quot;:1944,&quot;height&quot;:1036,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FKS1C1846OL3N%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1679,&quot;dateInserted&quot;:&quot;2026-08-28T10:47:38+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FKS1C1846OL3N%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/KS1C1846OL3N/image.png" alt="image.png" height="1036" width="1944" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/KS1C1846OL3N/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/KS1C1846OL3N/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/KS1C1846OL3N/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/KS1C1846OL3N/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/KS1C1846OL3N/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/KS1C1846OL3N/image.png 2000w, https://us.v-cdn.net/6038601/uploads/KS1C1846OL3N/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 1. </strong>Representation of the systematic step-by-step protocol optimization approach. In Step 1, the optimal quantum iterative reconstruction level (14) was identified. In Step 2, the different slice thicknesses were tested from 0.4 to 8 mm. In Step 3, the virtual monoenergetic image reconstruction level of the late iodine enhancement scan was optimized from 40 to 90 keV. The parameter with the best diagnostic performance in each step was retained in the subsequent step.</p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Cardiac / myocardium</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>QuantumPlus</p></td></tr><tr><td><p><strong>Acquisition mode</strong></p></td><td><p>PCCT spectral cardiac acquisition</p></td></tr><tr><td><p><strong>Tube voltage [kV]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>44 CCTA; 55 late iodine enhancement</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>CARE Dose4D</p></td></tr><tr><td><p><strong>Rotation time [s]</strong></p></td><td><p>0.25</p></td></tr><tr><td><p><strong>Detector slice collimation</strong></p></td><td><p>144 × 0.4 mm</p></td></tr><tr><td><p><strong>ECG gating</strong></p></td><td><p>Prospective ECG-triggered</p></td></tr><tr><td><p><strong>CCTA ECG window</strong></p></td><td><p>30–80% of RR interval</p></td></tr><tr><td><p><strong>Late iodine enhancement timing</strong></p></td><td><p>5 min after contrast administration</p></td></tr><tr><td><p><strong>Late iodine enhancement ECG timing</strong></p></td><td><p>Fixed 280-ms delay from R-wave</p></td></tr><tr><td><p><strong>Baseline slice thickness / increment [mm]</strong></p></td><td><p>1.5 / 1.0</p></td></tr><tr><td><p><strong>Baseline kernel</strong></p></td><td><p>Qr40</p></td></tr><tr><td><p><strong>Baseline iterative reconstruction</strong></p></td><td><p>QIR 3</p></td></tr><tr><td><p><strong>Baseline reconstruction energy</strong></p></td><td><p>65 keV</p></td></tr><tr><td><p><strong>QIR levels tested</strong></p></td><td><p>QIR 1–4</p></td></tr><tr><td><p><strong>Slice thickness / increment tested [mm]</strong></p></td><td><p>0.4/0.3; 1.5/1.0; 3.0/2.5; 5.0/4.0; 8.0/7.0</p></td></tr><tr><td><p><strong>VMI energies tested</strong></p></td><td><p>40, 45, 50, 55, 60, 65, 70, 90 keV</p></td></tr><tr><td><p><strong>Optimal reconstruction</strong></p></td><td><p><strong>QIR 4; 0.4/0.3 mm; 45 keV</strong></p></td></tr><tr><td><p><strong>ECV reconstruction</strong></p></td><td><p>Iodine maps generated from late iodine enhancement scan</p></td></tr><tr><td><p><strong>Contrast agent</strong></p></td><td><p>Iopromide, Ultravist 370 mg I/mL</p></td></tr><tr><td><p><strong>Contrast volume</strong></p></td><td><p>100 mL</p></td></tr><tr><td><p><strong>Saline flush</strong></p></td><td><p>20 mL</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>5–6 mL/s</p></td></tr></table></div><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p>27 patients undergoing same-day PCCT and MRI</p></td></tr><tr><td><p><strong>QIR effect</strong></p></td><td><p>No significant ECV difference across QIR 1–4, <em>p</em> = 1.000</p></td></tr><tr><td><p><strong>Best slice thickness</strong></p></td><td><p><strong>0.4 mm</strong>, CCC ≈ <strong>0.94</strong>, bias <strong>0.8%</strong></p></td></tr><tr><td><p><strong>Best VMI energy</strong></p></td><td><p><strong>45 keV</strong>, mean bias <strong>0.6%</strong></p></td></tr><tr><td><p><strong>Optimal reconstruction</strong></p></td><td><p><strong>QIR 4 + 0.4/0.3 mm + 45 keV</strong></p></td></tr><tr><td><p><strong>Improvement vs baseline</strong></p></td><td><p><strong>63% lower mean bias</strong> and <strong>6% higher concordance</strong> with MRI</p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
Gnasso C, Pinos D, Schoepf UJ, Vecsey-Nagy M, Aquino GJ, Fink N, Zsarnoczay E, Holtackers RJ, Stock J, Suranyi P, Varga-Szemes A, Emrich T. <em>Impact of reconstruction parameters on the accuracy of myocardial extracellular volume quantification on a first-generation, photon-counting detector CT.</em> <strong>European Radiology Experimental.</strong> 2024;8:70. doi:10.1186/s41747-024-00469-7.</p>]]>
        </description>
    </item>
    <item>
        <title>(2024) Fink | Safety-net PCCT VNC improves subtle coronary calcium detection</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/501/2024-fink-safety-net-pcct-vnc-improves-subtle-coronary-calcium-detection</link>
        <pubDate>Fri, 28 Aug 2026 10:44:12 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">501@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>Standard PCCT virtual noncontrast (VNC) calcium scoring performs well for larger and denser plaques but can miss subtle disease. Large/medium and high/medium-density plaques showed strong agreement with true noncontrast (TNC) scoring (r &gt; 0.9; ICC ≥ 0.90), whereas low-density plaques showed poor agreement and small plaques were not detectable with standard VNC reconstruction.</p><p></p><p>A dedicated “safety-net” reconstruction combining thinner 1.0-mm slices, a sharper Qr44 kernel, low monoenergetic energy and lower calcium thresholds markedly improved subtle-plaque detection. The best clinical setting was 55 keV, QIR 2, and a 110-HU threshold.</p><p></p><p>In 63 participants, standard VNC missed 56 plaques visible on TNC; the optimal safety-net reconstruction recovered 50/56 (89%). The approach may therefore be particularly valuable when standard VNC yields a calcium score of zero, potentially preventing false-negative risk classification while supporting elimination of a separate TNC scan.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fpubs.rsna.org%2Fdoi%2F10.1148%2Fryct.230328" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/WLH9CD6E09FF\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:1919996,&quot;width&quot;:2075,&quot;height&quot;:1338,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FWLH9CD6E09FF%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1677,&quot;dateInserted&quot;:&quot;2026-08-28T10:40:55+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FWLH9CD6E09FF%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/WLH9CD6E09FF/image.png" alt="image.png" height="1338" width="2075" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/WLH9CD6E09FF/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/WLH9CD6E09FF/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/WLH9CD6E09FF/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/WLH9CD6E09FF/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/WLH9CD6E09FF/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/WLH9CD6E09FF/image.png 2000w, https://us.v-cdn.net/6038601/uploads/WLH9CD6E09FF/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 7</strong>: Example axial CT reconstructions of in vivo coronary artery calcium scoring (CACS) without and with calcium scoring overlay, comparing CACSTNC (left column: 70 keV, quantum iterative reconstruction [QIR] off) and CACSVNC (middle column: 55 keV, QIR 1, as previously recommended) (9) at standard CACS settings with CACSVNC at the proposed safety net reconstruction (right column: 55 keV, QIR 2). The upper row (participant 1) shows CT scans in a 90-year-old male, the middle row (participant 2) in a 62-year-old male, and the lower row (participant 3) in a 59-year-old female. The safety net reconstruction allowed improved detection of small and/or low-density in vivo plaques (arrowheads) that initially were detected in reference TNC scans but not in standard VNC reconstructions. LAD = left anterior descending artery, RCA = right coronary artery, TNC = true noncontrast, VNC = virtual noncontrast. </p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha, VA40</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Coronary arteries / cardiac CT</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>QuantumPlus</p></td></tr><tr><td><p><strong>Tube voltage [kV]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>Rotation time [s]</strong></p></td><td><p>0.25</p></td></tr><tr><td><p><strong>Detector slice collimation</strong></p></td><td><p>144 × 0.4 mm</p></td></tr><tr><td><p><strong>ECG gating</strong></p></td><td><p>ECG-triggered</p></td></tr><tr><td><p><strong>Reference TNC reconstruction</strong></p></td><td><p>70 keV, QIR off</p></td></tr><tr><td><p><strong>Standard TNC slice thickness / increment [mm]</strong></p></td><td><p>3.0 / 1.5</p></td></tr><tr><td><p><strong>Standard TNC kernel</strong></p></td><td><p>Qr36</p></td></tr><tr><td><p><strong>VNC reconstruction energies</strong></p></td><td><p>55–80 keV in 5-keV increments</p></td></tr><tr><td><p><strong>VNC iterative reconstruction</strong></p></td><td><p>QIR 1–4</p></td></tr><tr><td><p><strong>Standard VNC slice thickness</strong></p></td><td><p>3.0 mm</p></td></tr><tr><td><p><strong>Standard VNC kernel</strong></p></td><td><p>Qr36</p></td></tr><tr><td><p><strong>Safety-net slice thickness / increment [mm]</strong></p></td><td><p>1.0 / 1.0</p></td></tr><tr><td><p><strong>Safety-net kernel</strong></p></td><td><p>Qr44</p></td></tr><tr><td><p><strong>Preferred safety-net reconstruction</strong></p></td><td><p><strong>55 keV, QIR 2</strong></p></td></tr><tr><td><p><strong>Preferred calcium threshold</strong></p></td><td><p><strong>110 HU</strong></p></td></tr><tr><td><p><strong>Contrast agent</strong></p></td><td><p>Iopromide 350 mg I/mL</p></td></tr><tr><td><p><strong>Contrast protocol</strong></p></td><td><p>50 mL contrast → 20 mL 50% contrast/saline → 25 mL saline</p></td></tr><tr><td><p><strong>Bolus triggering</strong></p></td><td><p>Descending aorta, 150 HU</p></td></tr><tr><td><p><strong>Trigger delay</strong></p></td><td><p>8 s</p></td></tr><tr><td><p><strong>Patient preparation</strong></p></td><td><p>0.4 mg sublingual nitroglycerin; 5 mg oral metoprolol if HR &gt;70 bpm</p></td></tr></table></div><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Clinical cohort</strong></p></td><td><p>63 participants; mean age <strong>57.8 ± 15.5 years</strong></p></td></tr><tr><td><p><strong>Large/medium or denser plaques</strong></p></td><td><p>VNC vs TNC: <strong>r &gt; 0.9; ICC ≥ 0.90</strong></p></td></tr><tr><td><p><strong>Low-density plaques, standard VNC</strong></p></td><td><p>Poor agreement: <strong>r = 0.5–0.6; ICC = 0.20–0.48</strong></p></td></tr><tr><td><p><strong>Small plaques, standard VNC</strong></p></td><td><p><strong>Not detectable</strong></p></td></tr><tr><td><p><strong>Best safety-net reconstruction</strong></p></td><td><p><strong>55 keV, QIR 2, Qr44, 1.0 mm, 110 HU</strong></p></td></tr><tr><td><p><strong>Clinical plaque recovery</strong></p></td><td><p><strong>50/56 (89%)</strong> previously missed plaques detected</p></td></tr></table></div><p></p><p><strong>Source:</strong><br />
Fink N, Emrich T, Schoepf UJ, Zsarnoczay E, O’Doherty J, Halfmann MC, Griffith JP III, et al. <em>Improved Detection of Small and Low-Density Plaques in Virtual Noncontrast Imaging–based Calcium Scoring at Photon-Counting Detector CT.</em> <strong>Radiology: Cardiothoracic Imaging.</strong> 2024;6(4). doi:10.1148/ryct.230328.</p>]]>
        </description>
    </item>
    <item>
        <title>(2022) Emrich | CCTA-based calcium scoring with virtual noniodine PCCT</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/500/2022-emrich-ccta-based-calcium-scoring-with-virtual-noniodine-pcct</link>
        <pubDate>Fri, 28 Aug 2026 10:37:16 +0000</pubDate>
        <category>Scientific publications</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">500@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>Evaluated whether coronary artery calcium scoring (CACS) can be derived directly from contrast-enhanced CCTA using the PCCT-specific PureCalcium virtual noniodine reconstruction, potentially eliminating the separate true noncontrast (TNC) calcium-score acquisition.</p><p><br />
Tested on a first-generation dual-source photon-counting CT in a phantom and 67 patients, comparing PureCalcium with conventional virtual noncontrast (VNC) and TNC reference images.</p><p><br />
PureCalcium substantially outperformed conventional VNC. In vivo, correlation with TNC calcium scores was very high (r = 0.97; ICC = 0.98), although PureCalcium still systematically underestimated absolute calcium burden.<br /></p><p>Conventional VNC showed much greater underestimation: median CACS 24.3 with VNC vs 232.2 with TNC, compared with 169.3 with PureCalcium vs 232.2 with TNC.</p><p><br />
Importantly for clinical risk stratification, calcium-score category agreement was excellent with PureCalcium (κ = 0.88) versus only moderate with VNC (κ = 0.60).</p><p><br />
PCCT takeaway: spectral information from a single contrast-enhanced CCTA acquisition can be used to separate iodine from calcium much more effectively than conventional VNC. </p><p></p><p>This creates the possibility of obtaining both coronary anatomy and clinically useful calcium scoring from one scan, potentially reducing additional acquisitions, scan time, and radiation exposure. Absolute CACS underestimation remains an important limitation.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fwww.ovid.com%2Fjnls%2Finvestigativeradiology%2Fabstract%2F10.1097%2Frli.0000000000000868%7Ecoronary-computed-tomography-angiography-based-calcium" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><p><strong>Source:</strong> Emrich T, Aquino G, Schoepf UJ, et al. Coronary Computed Tomography Angiography-Based Calcium Scoring: In Vitro and In Vivo Validation of a Novel Virtual Noniodine Reconstruction Algorithm on a Clinical, First-Generation Dual-Source Photon Counting-Detector System. Investigative Radiology. 2022;57(8):536–543. doi:10.1097/RLI.0000000000000868.</p>]]>
        </description>
    </item>
    <item>
        <title>(2023) Aquino | PCCT ECV mapping correlates strongly with cardiac MRI</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/498/2023-aquino-pcct-ecv-mapping-correlates-strongly-with-cardiac-mri</link>
        <pubDate>Fri, 28 Aug 2026 10:27:35 +0000</pubDate>
        <category>Publication protocols</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">498@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In this prospective same-day comparison of 29 patients, myocardial extracellular volume (ECV) measured with PCCT showed strong agreement with cardiac MRI, supporting spectral PCCT as a quantitative tool for myocardial tissue characterization. </p><p></p><p>Dual-energy PCCT achieved correlations of r = 0.91 for global ECV and r = 0.82 for midventricular ECV versus MRI. Dual-energy PCCT slightly overestimated ECV by approximately 2%, whereas the single-energy approach underestimated ECV by approximately 3%. Despite this small systematic bias, reliability versus MRI was good to excellent, with ICCs of 0.90 globally and 0.81 at the midventricular level for dual-energy PCCT. </p><p></p><p>A major advantage of the spectral approach was that dual-energy ECV required only the late-enhancement acquisition, eliminating the true unenhanced scan needed for single-energy ECV. This reduced radiation exposure by 40% (CTDIvol 10.1 vs 16.8 mGy) while also reducing potential interscan registration errors.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fpubs.rsna.org%2Fdoi%2F10.1148%2Fradiol.222030" rel="nofollow noopener ugc" role="button">Access publication</a></p><p></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/WZ2TEENIR7XI\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:639189,&quot;width&quot;:1000,&quot;height&quot;:575,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FWZ2TEENIR7XI%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1675,&quot;dateInserted&quot;:&quot;2026-08-28T10:26:07+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FWZ2TEENIR7XI%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/WZ2TEENIR7XI/image.png" alt="image.png" height="575" width="1000" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/WZ2TEENIR7XI/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/WZ2TEENIR7XI/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/WZ2TEENIR7XI/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/WZ2TEENIR7XI/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/WZ2TEENIR7XI/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/WZ2TEENIR7XI/image.png 2000w, https://us.v-cdn.net/6038601/uploads/WZ2TEENIR7XI/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Figure 3.</strong> Images show subepicardial late enhancement in a 50-year-old woman with history of arrhythmogenic right ventricular cardiomyopathy. Short- and long-axis cardiac MRI and CT scans demonstrate patchy left ventricular midmyocardial and subepicardial involvement. Enhancement pattern may suggest arrhythmogenic right ventricular cardiomyopathy with left ventricular involvement, although remote myocarditis cannot be ruled out. (A–C) Top row: Images show (A) basal and (B) midventricular short-axis late gadolinium enhancement (LGE) MRI scans with subepicardial involvement (arrows), similarly in (C) the long-axis image. (D–F) Middle row: Images are corresponding CT extracellular volume (ECV) maps showing a similar pattern of myocardial involvement (arrows). (G–I) Bottom row: Images show (G, H) corresponding, short-axis MRI ECV maps demonstrating similar areas of involvement (arrows), and a (I) representative CT ECV American Heart Association 17-segment subepicardiac (50% to outer 10% of the myocardial wall) polar map, which shows the hematocrit (Hct) and the global ECV mean, as well as the means and SDs of ECV for each myocardial segment.</p><p></p><h2 data-id="protocol">Protocol</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Detail</strong></p></th><th><p><strong>Value</strong></p></th></tr><tr><td><p><strong>Scanner</strong></p></td><td><p>NAEOTOM Alpha</p></td></tr><tr><td><p><strong>Scan area</strong></p></td><td><p>Cardiac / myocardium</p></td></tr><tr><td><p><strong>Scan mode</strong></p></td><td><p>QuantumPlus sequential</p></td></tr><tr><td><p><strong>Acquisition mode</strong></p></td><td><p>PCCT, full spectral data</p></td></tr><tr><td><p><strong>Scan direction</strong></p></td><td><p>Axial</p></td></tr><tr><td><p><strong>Tube voltage [kV]</strong></p></td><td><p>120</p></td></tr><tr><td><p><strong>Effective mAs [mAs]</strong></p></td><td><p>CARE Dose4D automatic</p></td></tr><tr><td><p><strong>IQ level</strong></p></td><td><p>20 unenhanced; 44 CCTA; 50 late enhancement</p></td></tr><tr><td><p><strong>Dose modulation</strong></p></td><td><p>CARE Dose4D</p></td></tr><tr><td><p><strong>CTDIvol [mGy]</strong></p></td><td><p>Dual-energy ECV: 10.1; single-energy ECV: 16.8</p></td></tr><tr><td><p><strong>DLP [mGy·cm]</strong></p></td><td><p>Dual-energy ECV: 148; single-energy ECV: 248</p></td></tr><tr><td><p><strong>Rotation time [s]</strong></p></td><td><p>0.25</p></td></tr><tr><td><p><strong>Acquisition slice thickness [mm]</strong></p></td><td><p>0.4</p></td></tr><tr><td><p><strong>Reconstruction slice width [mm]</strong></p></td><td><p>1.5</p></td></tr><tr><td><p><strong>Reconstruction increment [mm]</strong></p></td><td><p>1.0</p></td></tr><tr><td><p><strong>Reconstruction kernel</strong></p></td><td><p>Qr40</p></td></tr><tr><td><p><strong>Iterative reconstruction</strong></p></td><td><p>QIR 3</p></td></tr><tr><td><p><strong>Reconstruction energy</strong></p></td><td><p>65 keV</p></td></tr><tr><td><p><strong>Reconstruction comparison</strong></p></td><td><p>Single-energy ECV vs dual-energy iodine-based ECV</p></td></tr><tr><td><p><strong>ECG gating</strong></p></td><td><p>ECG-triggered</p></td></tr><tr><td><p><strong>ECG window</strong></p></td><td><p>280 ms RR interval for unenhanced and late enhancement; 30–80% RR for CCTA</p></td></tr><tr><td><p><strong>Contrast agent</strong></p></td><td><p>Iopromide, Ultravist 370 mg I/mL</p></td></tr><tr><td><p><strong>Contrast volume</strong></p></td><td><p>100 mL</p></td></tr><tr><td><p><strong>Saline flush</strong></p></td><td><p>20 mL</p></td></tr><tr><td><p><strong>Injection rate</strong></p></td><td><p>5–6 mL/s</p></td></tr><tr><td><p><strong>Bolus triggering</strong></p></td><td><p>n.a.</p></td></tr><tr><td><p><strong>Late-enhancement phase</strong></p></td><td><p>5 min after contrast administration</p></td></tr><tr><td><p><strong>ECV reconstruction</strong></p></td><td><p>Dual-energy iodine maps from late-enhancement scan; automated 17-segment ECV maps</p></td></tr></table></div><p></p><h2 data-id="key-results">Key Results</h2><div><table><colgroup><col /><col /><col /></colgroup><tr><th><p><strong>Parameter</strong></p></th><th><p><strong>Main finding</strong></p></th></tr><tr><td><p><strong>Study population</strong></p></td><td><p>29 patients</p></td></tr><tr><td><p><strong>Global ECV, dual-energy PCCT vs MRI</strong></p></td><td><p><strong>r = 0.91; ICC = 0.90</strong></p></td></tr><tr><td><p><strong>Midventricular ECV</strong></p></td><td><p><strong>r = 0.82; ICC = 0.81</strong></p></td></tr><tr><td><p><strong>Dual-energy bias</strong></p></td><td><p>ECV overestimated by <strong>1.9% globally</strong></p></td></tr><tr><td><p><strong>Radiation reduction</strong></p></td><td><p><strong>40%</strong> with dual- vs single-energy ECV</p></td></tr><tr><td><p><strong>Clinical implication</strong></p></td><td><p>Spectral PCCT may add quantitative myocardial tissue characterization to cardiac CT without requiring an additional unenhanced scan</p></td></tr></table></div><p><strong>Source:</strong><br />
Aquino GJ, O’Doherty J, Schoepf UJ, Ellison B, Byrne J, Fink N, Zsarnoczay E, et al. <em>Myocardial Characterization with Extracellular Volume Mapping with a First-Generation Photon-counting Detector CT with MRI Reference.</em> <strong>Radiology.</strong> 2023;307(2). doi:10.1148/radiol.222030.</p>]]>
        </description>
    </item>
    <item>
        <title>(2025) Dang | Low-dose 70 kV vs 120kV PCCT for infant cardiac imaging</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/493/2025-dang-low-dose-70-kv-vs-120kv-pcct-for-infant-cardiac-imaging</link>
        <pubDate>Fri, 28 Aug 2026 09:42:55 +0000</pubDate>
        <category>Scientific publications</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">493@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>In 58 infants &lt;10 kg, cardiac PCCT at 70 kV and 120 kV provided comparable image quality, with similar aortic CNR and median subjective image-quality scores of 5/5 in both groups.</p><p></p><p>70 kV reduced radiation dose by almost 50%, with CTDI decreasing from 0.25 mGy at 120 kV to 0.13 mGy at 70 kV (P&lt;0.001).</p><p></p><p>The key trade-off is that 70 kV does not provide the advanced spectral reconstructions available at 120 kV, making protocol selection a balance between minimum dose and spectral capability.</p></div></div><p> <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fdoi.org%2F10.1007%2Fs00247-025-06467-0" rel="nofollow noopener ugc" role="button">Access publication</a></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/6D7EHL5COHGN\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:271281,&quot;width&quot;:685,&quot;height&quot;:390,&quot;displaySize&quot;:&quot;large&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F6D7EHL5COHGN%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1672,&quot;dateInserted&quot;:&quot;2026-08-28T09:39:40+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2F6D7EHL5COHGN%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/6D7EHL5COHGN/image.png" alt="image.png" height="390" width="685" data-display-size="large" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/6D7EHL5COHGN/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/6D7EHL5COHGN/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/6D7EHL5COHGN/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/6D7EHL5COHGN/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/6D7EHL5COHGN/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/6D7EHL5COHGN/image.png 2000w, https://us.v-cdn.net/6038601/uploads/6D7EHL5COHGN/image.png" sizes="100vw" /></a>
    </span>
</span>
<p><strong>Source:</strong> Dang NH, Zhou W, Arguello Fletes GM, <em>et al.</em> <em>Pediatr Radiol.</em> Published online November 18, 2025. doi:10.1007/s00247-025-06467-0.</p><p></p><p>Furthermore, there is a commentary by Kelly Horst and Lifeng Yu.</p><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs00247-025-06479-w" rel="nofollow noopener ugc" role="button">Access publication</a></p><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Flink.springer.com%2Fepdf%2F10.1007%2Fs00247-025-06479-w%3Fsharing_token%3Dqw-J6-5uxrkwKTPMSFTFmve4RwlQNchNByi7wbcMAY7-1I44Z-zYplFNhiC2hhR9i1yg0ZNFCaNSoM4WdMvbHUbW0F9Jkst-gl4qGFJQ6ppnbYu_OteyA6lV8QMY2qpX2JNsxrZ6Iq61Z23kvZbpXtZesdKNHSphB32VHFkFu2Q%253D" rel="nofollow noopener ugc" role="button">PDF commentary</a></p><div><div><p>With modern <strong>PCCT</strong>, pediatric cardiac CT can already achieve <strong>sub-mSv radiation doses</strong>; the commentary argues that further dose reduction should not automatically take priority when it compromises <strong>spatial resolution, image noise, edge sharpness, or diagnostic confidence</strong>.</p><p></p><p>Lower-kV PCCT protocols may reduce radiation dose, but there are important trade-offs: <strong>70–90 kV Quantum mode can sacrifice ultra-high spatial resolution and material-specific spectral imaging</strong>, whereas <strong>120–140 kV Quantum Plus mode</strong> enables low-keV VMI and spectral reconstructions such as virtual non-calcium and iodine-only imaging—potentially valuable for cardiovascular assessment.</p><p></p><p>The authors propose a shift from <strong>ALARA toward optimizing diagnostic performance and clinical impact</strong>: PCCT protocols should preserve sufficient image quality not only for human interpretation, but also for <strong>quantitative imaging, radiomics and AI</strong>, whose performance and reproducibility may deteriorate as radiation dose decreases and image noise increases.</p></div></div><p><strong>Source:</strong> Horst K, Yu L. <em>Pediatr Radiol.</em> 2025;56:554–555.</p>]]>
        </description>
    </item>
    <item>
        <title>(2026) Tóth | Spectral black-blood PCCT for high-resolution carotid vessel wall imaging</title>
        <link>https://connect.siemens-healthineers.com/zh/discussion/488/2026-toth-spectral-black-blood-pcct-for-high-resolution-carotid-vessel-wall-imaging</link>
        <pubDate>Fri, 28 Aug 2026 05:37:26 +0000</pubDate>
        <category>Scientific publications</category>
        <dc:creator>Daniel Stromer</dc:creator>
        <guid isPermaLink="false">488@/zh/discussions</guid>
        <description><![CDATA[<div><div><p>A novel spectral black-blood CT (BBCT) reconstruction used the spectral information from PCCT to suppress intraluminal iodine from a routine single-phase CTA dataset, enabling high-resolution carotid vessel wall imaging without an additional scan, contrast administration, or dedicated acquisition. </p><p></p><p>Compared with conventional CTA, spectral BBCT significantly improved wall–lumen delineation and carotid plaque conspicuity while preserving overall image quality. An iodine ratio of 2.0 provided the best balance between lumen suppression and vessel wall visualization. </p><p></p><p>BBCT improved reader agreement for high-risk plaque features including intraplaque hemorrhage, lipid-rich necrotic core, and thin fibrous cap. However, possible subtraction-related sensitivity loss means BBCT should currently be viewed as a complementary PCCT reconstruction alongside conventional CTA, rather than a standalone replacement.</p></div></div><p><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fdoi.org%2F10.1097%2FRLI.0000000000001309" rel="nofollow noopener ugc" role="button">Access publication</a></p><span data-embedjson="{&quot;url&quot;:&quot;https:\/\/us.v-cdn.net\/6038601\/uploads\/NU81W6U79REN\/image.png&quot;,&quot;name&quot;:&quot;image.png&quot;,&quot;type&quot;:&quot;image\/png&quot;,&quot;size&quot;:759196,&quot;width&quot;:800,&quot;height&quot;:1023,&quot;displaySize&quot;:&quot;medium&quot;,&quot;float&quot;:&quot;none&quot;,&quot;downloadUrl&quot;:&quot;https:\/\/connect.siemens-healthineers.com\/api\/v2\/media\/download-by-url?url=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FNU81W6U79REN%2Fimage.png&quot;,&quot;active&quot;:true,&quot;mediaID&quot;:1658,&quot;dateInserted&quot;:&quot;2026-08-28T05:36:27+00:00&quot;,&quot;insertUserID&quot;:14,&quot;foreignType&quot;:null,&quot;foreignID&quot;:null,&quot;embedType&quot;:&quot;image&quot;,&quot;embedStyle&quot;:&quot;rich_embed_card&quot;}">
    <span>
        <a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Fus.v-cdn.net%2F6038601%2Fuploads%2FNU81W6U79REN%2Fimage.png" rel="nofollow noopener ugc" target="_blank">
            <img src="https://us.v-cdn.net/6038601/uploads/NU81W6U79REN/image.png" alt="image.png" height="1023" width="800" data-display-size="medium" data-float="none" data-type="image/png" data-embed-type="image" srcset="https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=300, width=300/6038601/uploads/NU81W6U79REN/image.png 300w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=600, width=600/6038601/uploads/NU81W6U79REN/image.png 600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=800, width=800/6038601/uploads/NU81W6U79REN/image.png 800w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1200, width=1200/6038601/uploads/NU81W6U79REN/image.png 1200w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=1600, width=1600/6038601/uploads/NU81W6U79REN/image.png 1600w, https://us.v-cdn.net/cdn-cgi/image/quality=80, format=auto, fit=scale-down, height=2000, width=2000/6038601/uploads/NU81W6U79REN/image.png 2000w, https://us.v-cdn.net/6038601/uploads/NU81W6U79REN/image.png" sizes="100vw" /></a>
    </span>
</span>
<p>Check also the LinkedinPost:<strong><br />
→ </strong><a href="https://connect.siemens-healthineers.com/zh/home/leaving?allowTrusted=1&amp;target=https%3A%2F%2Flnkd.in%2Fp%2Fdcs--t_6" rel="nofollow noopener ugc">Go to post</a></p><p><strong>Source:</strong> Tóth A, Hagar MT, Halfmann MC, <em>et al.</em> <em>Investigative Radiology.</em> Published ahead of print August 18, 2026. doi:10.1097/RLI.0000000000001309.</p>]]>
        </description>
    </item>
   </channel>
</rss>
